BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-380. [PMID: 28130846 DOI: 10.1002/hep.29086] [Cited by in Crossref: 1290] [Cited by in F6Publishing: 1210] [Article Influence: 322.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Mao Y, Huang M. Letter to the Editor: Should Growth Pattern of Hepatocellular Carcinoma Be Constant and Homogenous? Hepatology 2021;73:2617-8. [PMID: 33205459 DOI: 10.1002/hep.31640] [Reference Citation Analysis]
2 Fu C, Li J, Li P, Cheng D. LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b. Cancer Manag Res 2021;13:8575-83. [PMID: 34815712 DOI: 10.2147/CMAR.S321111] [Reference Citation Analysis]
3 Aggarwal A, Horwitz JK, Dolan D, Kamath A, Lewis S, Facciuto M, Grewal P, Fiel MI, Schiano T, Facciuto ME. Hypo-vascular hepatocellular carcinoma and liver transplantation: Morphological characteristics and implications on outcomes. J Surg Oncol 2019;120:1112-8. [PMID: 31486087 DOI: 10.1002/jso.25700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Abdelaziz AO, Nabil MM, Omran DA, Abdelmaksoud AH, Asem N, Shousha HI, Elbaz TM, Leithy R. Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC. Arab J Gastroenterol 2020;21:102-5. [PMID: 32439235 DOI: 10.1016/j.ajg.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
6 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Li B, Liu A, Wen Y, Yang G, Zhao J, Li X, Mao Y, Li B. The prognostic values of serum markers in hepatocellular carcinoma after invasive therapies based on real-world data. J Clin Lab Anal 2021;35:e23932. [PMID: 34403527 DOI: 10.1002/jcla.23932] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Torres HA, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis.Gastroenterology. 2019;157:909-916. [PMID: 30797794 DOI: 10.1053/j.gastro.2019.01.271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
9 Chong HH, Yang L, Sheng RF, Yu YL, Wu DJ, Rao SX, Yang C, Zeng MS. Multi-scale and multi-parametric radiomics of gadoxetate disodium-enhanced MRI predicts microvascular invasion and outcome in patients with solitary hepatocellular carcinoma ≤ 5 cm. Eur Radiol 2021;31:4824-38. [PMID: 33447861 DOI: 10.1007/s00330-020-07601-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
10 He Y, Liang T, Mo S, Chen Z, Zhao S, Zhou X, Yan L, Wang X, Su H, Zhu G, Han C, Peng T. Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models. BMC Gastroenterol 2021;21:230. [PMID: 34020603 DOI: 10.1186/s12876-021-01815-4] [Reference Citation Analysis]
11 Spence AB, Levy ME, Monroe A, Castel A, Timpone J, Horberg M, Adams-Campbell L, Kumar P. Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. J Community Health 2021;46:75-85. [PMID: 32424501 DOI: 10.1007/s10900-020-00844-6] [Reference Citation Analysis]
12 Ziol M, Poté N, Amaddeo G, Laurent A, Nault J, Oberti F, Costentin C, Michalak S, Bouattour M, Francoz C, Pageaux GP, Ramos J, Decaens T, Luciani A, Guiu B, Vilgrain V, Aubé C, Derman J, Charpy C, Zucman-rossi J, Barget N, Seror O, Ganne-carrié N, Paradis V, Calderaro J. Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology 2018;68:103-12. [DOI: 10.1002/hep.29762] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
13 Labeur TA, Achterbergh R, Takkenberg B, Van Delden O, Mathôt R, Klümpen HJ. Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study. Oncologist 2020;25:e1274-9. [PMID: 31645371 DOI: 10.1634/theoncologist.2019-0718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
15 Shin H, Jung YW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim YY, Choi JY, Kim SU. Risk assessment of hepatocellular carcinoma development for indeterminate hepatic nodules in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:390-9. [PMID: 31146508 DOI: 10.3350/cmh.2018.0103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
16 Benmassaoud A, Nitulescu R, Pembroke T, Halme AS, Ghali P, Deschenes M, Wong P, Klein MB, Sebastiani G. Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis. Clin Infect Dis 2019;69:1422-30. [PMID: 30561558 DOI: 10.1093/cid/ciy1082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Lee CM, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int 2021;15:676-84. [PMID: 33956288 DOI: 10.1007/s12072-021-10190-x] [Reference Citation Analysis]
18 Wang J, Ye X, Li J, He S. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore) 2021;100:e24602. [PMID: 33578564 DOI: 10.1097/MD.0000000000024602] [Reference Citation Analysis]
19 Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C. Should Patients With NAFLD/NASH Be Surveyed for HCC? Transplantation 2019;103:39-44. [DOI: 10.1097/tp.0000000000002361] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 8.7] [Reference Citation Analysis]
20 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lee PC, Chao Y, Chen MH, Lan KH, Lee CJ, Lee IC, Chen SC, Hou MC, Huang YH. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E182. [PMID: 31940757 DOI: 10.3390/cancers12010182] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
22 Russo FP, Imondi A, Lynch EN, Farinati F. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018;50:640-646. [PMID: 29636240 DOI: 10.1016/j.dld.2018.03.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
23 Zhou C, Peng Y, Zhou K, Zhang L, Zhang X, Yu L, Hu J, Chen F, Qiu S, Zhou J, Fan J, Ren Z, Wang Z. Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:19-28. [PMID: 30881962 DOI: 10.21037/hbsn.2018.11.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
24 Greten TF, Lai CW, Li G, Staveley-O'Carroll KF. Targeted and Immune-Based Therapies for Hepatocellular Carcinoma. Gastroenterology 2019;156:510-24. [PMID: 30287171 DOI: 10.1053/j.gastro.2018.09.051] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 13.8] [Reference Citation Analysis]
25 Longerich T, Schirmacher P. Emerging Role of the Pathologist in Precision Medicine for HCC. Dig Dis Sci 2019;64:928-33. [PMID: 30815826 DOI: 10.1007/s10620-019-05548-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 2021;21:182. [PMID: 33879085 DOI: 10.1186/s12876-021-01765-x] [Reference Citation Analysis]
27 Kim DW, Kim SY, Kang HJ, Kang JH, Lee SS, Shim JH, Choi SH, Shin YM, Byun JH. Diagnostic performance of ultrasonography-guided core-needle biopsy according to MRI LI-RADS diagnostic categories. Ultrasonography 2021;40:387-97. [PMID: 33472289 DOI: 10.14366/usg.20110] [Reference Citation Analysis]
28 Woolen SA, Singal AG, Davenport MS, Troost JP, Khalatbari S, Mittal S, Siddiqui S, Fobar A, Morris J, Odewole M, Tapper EB, Pillai A, Parikh ND. Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00202-0. [PMID: 33618022 DOI: 10.1016/j.cgh.2021.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lin WC, Lin YS, Chang CW, Chang CW, Wang TE, Wang HY, Chen MJ. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS One. 2020;15:e0233212. [PMID: 32442193 DOI: 10.1371/journal.pone.0233212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Jian C, Fu J, Cheng X, Shen L, Ji Y, Wang X, Pan S, Tian H, Tian S, Liao R, Song K, Wang H, Zhang X, Wang Y, Huang Z, She Z, Zhang X, Zhu L, Li H. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. Cell Metabolism 2020;31:892-908.e11. [DOI: 10.1016/j.cmet.2020.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
31 Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20201928. [PMID: 33835138 DOI: 10.1042/BSR20201928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Wang G, Li J, Yao Y, Liu Y, Xia P, Zhang H, Yin M, Qin Z, Ma W, Yuan Y. Small nucleolar RNA 42 promotes the growth of hepatocellular carcinoma through the p53 signaling pathway. Cell Death Discov 2021;7:347. [PMID: 34759267 DOI: 10.1038/s41420-021-00740-5] [Reference Citation Analysis]
33 Cortese S, Morales J, Martín L, Kayser S, Colón A, Ramón E, Tellado JM. Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española 2020;98:9-17. [DOI: 10.1016/j.ciresp.2019.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang D, Wei Q, Wu GG, Zhang XY, Lu WW, Lv WZ, Liao JT, Cui XW, Ni XJ, Dietrich CF. Preoperative Prediction of Microvascular Invasion in Patients With Hepatocellular Carcinoma Based on Radiomics Nomogram Using Contrast-Enhanced Ultrasound. Front Oncol 2021;11:709339. [PMID: 34557410 DOI: 10.3389/fonc.2021.709339] [Reference Citation Analysis]
35 Langhans B, Nischalke HD, Krämer B, Dold L, Lutz P, Mohr R, Vogt A, Toma M, Eis-Hübinger AM, Nattermann J, Strassburg CP, Gonzalez-Carmona MA, Spengler U. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:2055-66. [PMID: 31724091 DOI: 10.1007/s00262-019-02427-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
36 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
37 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Reference Citation Analysis]
38 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Feng H, Yang C, Xu F, Zhao Y, Jin T, Wei Z, Wang D, Dai C. Therapeutic efficacy of microwave coagulation versus liver resection for hepatocellular carcinoma within the Milan criteria: A propensity score matching analysis. Eur J Surg Oncol 2021:S0748-7983(21)00725-3. [PMID: 34509336 DOI: 10.1016/j.ejso.2021.08.035] [Reference Citation Analysis]
40 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D; Cochrane Hepato-Biliary Group. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013362] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Chinnaratha MA, Campbell K, Mathias R, McCormick RJ, Woodman RJ, Wigg AJ. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. J Gastrointest Cancer 2019;50:888-93. [PMID: 30345486 DOI: 10.1007/s12029-018-0171-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Hu CL, Du QC, Wang ZX, Pang MQ, Wang YY, Li YY, Zhou Y, Wang HJ, Fan HN. Relationship between platelet-based models and the prognosis of patients with malignant hepatic tumors. Oncol Lett 2020;19:2384-96. [PMID: 32194738 DOI: 10.3892/ol.2020.11317] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Schoenberg MB, Anger HJW, Bucher JN, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visc Med 2020;36:506-15. [PMID: 33447607 DOI: 10.1159/000506752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Tayob N, Corley DA, Christie I, Almers L, Rahal AK, Richardson P, White DL, Davila J, Kanwal F, El-Serag HB. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. Clin Gastroenterol Hepatol. 2020;. [PMID: 32768590 DOI: 10.1016/j.cgh.2020.07.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Schoenberg MB, Bucher JN, Koch D, Börner N, Hesse S, De Toni EN, Seidensticker M, Angele MK, Klein C, Bazhin AV, Werner J, Guba MO. A novel machine learning algorithm to predict disease free survival after resection of hepatocellular carcinoma. Ann Transl Med 2020;8:434. [PMID: 32395478 DOI: 10.21037/atm.2020.04.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
46 Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastroenterol Hepatol 2018;2018:2784537. [PMID: 30065915 DOI: 10.1155/2018/2784537] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
47 Ren X, Ji Y, Jiang X, Qi X. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Biosci Rep 2018;38:BSR20181423. [PMID: 30355653 DOI: 10.1042/BSR20181423] [Reference Citation Analysis]
48 Paisant A, Gillard M, Oberti F, Roux M, Aubé C. Validation of a Diagnostic Algorithm for Hepatocellular Carcinoma at Gadoxetic Acid-enhanced MRI. Radiology 2021;300:184-6. [PMID: 33904774 DOI: 10.1148/radiol.2021204529] [Reference Citation Analysis]
49 Sagnelli E, Potenza N, Onorato L, Sagnelli C, Coppola N, Russo A. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma. World J Hepatol 2018; 10(9): 558-570 [PMID: 30310534 DOI: 10.4254/wjh.v10.i9.558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
50 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
52 Zhang H, Xiong F, Qian K, Liu Y, Liang B, Xiong B, Yang F, Zheng C. Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma. Cancer Manag Res 2019;11:981-96. [PMID: 30774426 DOI: 10.2147/CMAR.S189208] [Reference Citation Analysis]
53 Xie S, Zhang Y, Chen J, Jiang T, Liu W, Rong D, Sun L, Zhang L, He B, Wang J. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 2021. [PMID: 34773467 DOI: 10.1007/s00261-021-03339-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Tsauo J, Noh SY, Shin JH, Gwon DI, Han K, Lee JM, Jeon UB, Kim YH. Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study. Clin Radiol 2021;76:681-7. [PMID: 34140137 DOI: 10.1016/j.crad.2021.05.011] [Reference Citation Analysis]
56 Fan PL, Xia HS, Ding H, Dong Y, Chen LL, Wang WP. Characterization of Early Hepatocellular Carcinoma and High-Grade Dysplastic Nodules on Contrast-Enhanced Ultrasound: Correlation With Histopathologic Findings. J Ultrasound Med 2020;39:1799-808. [PMID: 32378794 DOI: 10.1002/jum.15288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Fatima T, Mumtaz H, Khan MH, Rasool S, Tayyeb M, Haider MZ, Hussain ST, Shahzad A, Ali S, Hussain T. Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy. Cureus 2020;12:e11565. [PMID: 33364092 DOI: 10.7759/cureus.11565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
59 Deng J, Chen W, Wu X, Zhou Y, Li J. Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e24060. [PMID: 33429769 DOI: 10.1097/MD.0000000000024060] [Reference Citation Analysis]
60 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Long Y, Zeng Q, He X, Ye H, Su Y, Zheng R, Yu J, Xu E, Li K. One-lung ventilation for percutaneous thermal ablation of liver tumors in the hepatic dome. Int J Hyperthermia 2020;37:49-54. [PMID: 31918592 DOI: 10.1080/02656736.2019.1708483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Vermersch M, Mulé S, Chalaye J, Galletto Pregliasco A, Emsen B, Amaddeo G, Monnet A, Stemmer A, Baranes L, Laurent A, Leroy V, Itti E, Luciani A. Impact of the 18F-FDG-PET/MRI on Metastatic Staging in Patients with Hepatocellular Carcinoma: Initial Results from 104 Patients. J Clin Med 2021;10:4017. [PMID: 34501465 DOI: 10.3390/jcm10174017] [Reference Citation Analysis]
63 Park HJ, Seo KI, Kim SJ, Lee SU, Yun BC, Han BH, Shin DH, Choi YI, Moon HH. Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Korean J Gastroenterol 2021;77:115-22. [PMID: 33658474 DOI: 10.4166/kjg.2020.148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Reference Citation Analysis]
65 Yi D, Wen-Ping W, Lee WJ, Meloni MF, Clevert DA, Cristina Chammas M, Tannapfel A, Forgione A, Dietrich CF. Hepatocellular carcinoma in the non-cirrhotic liver. Clin Hemorheol Microcirc 2021. [PMID: 34842182 DOI: 10.3233/CH-211309] [Reference Citation Analysis]
66 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Zou J, Zhu X, Xiang D, Zhang Y, Li J, Su Z, Kong L, Zhang H. LIX1-like protein promotes liver cancer progression via miR-21-3p-mediated inhibition of fructose-1,6-bisphosphatase. Acta Pharm Sin B 2021;11:1578-91. [PMID: 34221869 DOI: 10.1016/j.apsb.2021.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Wang F, Hou W, Chitsike L, Xu Y, Bettler C, Perera A, Bank T, Cotler SJ, Dhanarajan A, Denning MF, Ding X, Breslin P, Qiang W, Li J, Koleske AJ, Qiu W. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice. Gastroenterology 2020;159:289-305.e16. [PMID: 32171747 DOI: 10.1053/j.gastro.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
69 Song W, Yu X, Guo D, Liu H, Tang Z, Liu X, Zhou J, Zhang H, Liu Y. MRI-Based Radiomics: Associations With the Recurrence-Free Survival of Patients With Hepatocellular Carcinoma Treated With Conventional Transcatheter Arterial Chemoembolization.J Magn Reson Imaging. 2020;52:461-473. [PMID: 31675174 DOI: 10.1002/jmri.26977] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
70 Kim SW, Joo I, Kim H, Ahn SJ, Kang H, Jeon SK, Lee JM. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 2020;30:2861-70. [DOI: 10.1007/s00330-019-06623-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
71 Zhao Q, Xie L, Chen S, Xu X, Jiang T, Zheng S. Virtual navigation-guided radiofrequency ablation for recurrent hepatocellular carcinoma invisible on ultrasound after hepatic resection. Hepatobiliary & Pancreatic Diseases International 2020;19:532-40. [DOI: 10.1016/j.hbpd.2020.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Peng X, Lei C, He A, Luo R, Cai Y, Dong W. Upregulation of phosphatidylinositol glycan anchor biosynthesis class C is associated with unfavorable survival prognosis in patients with hepatocellular carcinoma. Oncol Lett 2021;21:237. [PMID: 33613726 DOI: 10.3892/ol.2021.12498] [Reference Citation Analysis]
73 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
75 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
76 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Di Martino M, García Septiem J, Maqueda González R, Muñoz de Nova JL, de la Hoz Rodríguez Á, Correa Bonito A, Martín-Pérez E. [Elective surgery during the SARS-CoV-2 pandemic (COVID-19): a morbimortality analysis and recommendations on patient prioritisation and security measures]. Cir Esp (Engl Ed) 2020;98:525-32. [PMID: 32408995 DOI: 10.1016/j.ciresp.2020.04.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
78 Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. J Viral Hepat 2019;26:596-602. [PMID: 30629790 DOI: 10.1111/jvh.13060] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
79 Xu G, Zhou X, Xing J, Xiao Y, Jin B, Sun L, Yang H, Du S, Xu H, Mao Y. Identification of RASSF1A promoter hypermethylation as a biomarker for hepatocellular carcinoma. Cancer Cell Int 2020;20:547. [PMID: 33292241 DOI: 10.1186/s12935-020-01638-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
80 Wang Y, Gao R, Li J, Tang S, Li S, Tong Q, Li S. Downregulation of hsa_circ_0074854 Suppresses the Migration and Invasion in Hepatocellular Carcinoma via Interacting with HuR and via Suppressing Exosomes-Mediated Macrophage M2 Polarization. Int J Nanomedicine 2021;16:2803-18. [PMID: 33880025 DOI: 10.2147/IJN.S284560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Yang H, Seon J, Sung PS, Oh JS, Lee HL, Jang B, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. Journal of Vascular and Interventional Radiology 2017;28:1503-1511.e2. [DOI: 10.1016/j.jvir.2017.07.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
82 Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. J Gastroenterol Hepatol 2019;34:2179-86. [PMID: 31062879 DOI: 10.1111/jgh.14705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
83 Yang Q, Wei J, Hao X, Kong D, Yu X, Jiang T, Xi J, Cai W, Luo Y, Jing X, Yang Y, Cheng Z, Wu J, Zhang H, Liao J, Zhou P, Song Y, Zhang Y, Han Z, Cheng W, Tang L, Liu F, Dou J, Zheng R, Yu J, Tian J, Liang P. Improving B-mode ultrasound diagnostic performance for focal liver lesions using deep learning: A multicentre study. EBioMedicine. 2020;56:102777. [PMID: 32485640 DOI: 10.1016/j.ebiom.2020.102777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
84 Gao Y, Chang X, Xia J, Sun S, Mu Z, Liu X. Identification of HCC-Related Genes Based on Differential Partial Correlation Network. Front Genet 2021;12:672117. [PMID: 34335688 DOI: 10.3389/fgene.2021.672117] [Reference Citation Analysis]
85 Varol Fİ. Pediatric Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1169-75. [PMID: 32856229 DOI: 10.1007/s12029-020-00494-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Krassenburg LAP, Zanjir WR, Georgie F, Stotland E, Janssen HLA, Hansen BE, Feld JJ. Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. Clin Infect Dis 2021;72:780-6. [PMID: 32052014 DOI: 10.1093/cid/ciaa144] [Reference Citation Analysis]
87 Rho YS, Pagano I, Wong LL, Kwee SA, Acoba JD. Factors and Survival Implications associated with biopsy of hepatocellular carcinoma. HPB (Oxford) 2021;23:1054-60. [PMID: 33229278 DOI: 10.1016/j.hpb.2020.11.001] [Reference Citation Analysis]
88 Lee DH, Lee JM, Yu MH, Hur BY, Yi N, Lee K, Suh K, Yoon J, Kim YJ, Lee J, Yu SJ, Han JK. Non-hypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MR can help determine the treatment method for HCC. Eur Radiol 2019;29:3122-31. [DOI: 10.1007/s00330-018-5941-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
89 Liu H, Zhao K, Liu X, Zhang Z, Qian J, Zhang C, Liang M. Diagnosis of hepatocellular carcinoma based on a terahertz signal and VMD-CWSE. Biomed Opt Express 2020;11:5045-59. [PMID: 33014599 DOI: 10.1364/BOE.392860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Choi DT, Davila JA, Sansgiry S, David E, Singh H, El-Serag HB, Hsiao-Fan Sada Y. Factors Associated With Delay of Diagnosis of Hepatocellular Carcinoma in Patients With Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1679-87. [PMID: 32693047 DOI: 10.1016/j.cgh.2020.07.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
91 Núñez KG, Sandow T, Fort D, Patel J, Hibino M, Carmody I, Cohen AJ, Thevenot P. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4765. [PMID: 34638251 DOI: 10.3390/cancers13194765] [Reference Citation Analysis]
92 Moon CM, Shin SS, Heo SH, Jeong YY. Metabolic Alterations Associated with Early-Stage Hepatocellular Carcinoma and Their Correlation with Aging and Enzymatic Activity in Patients with Viral Hepatitis-Induced Liver Cirrhosis: A Preliminary Study. J Clin Med 2020;9:E765. [PMID: 32178316 DOI: 10.3390/jcm9030765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Hou C, Guo D, Yu X, Wang S, Liu T. TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib. Biomed Pharmacother 2020;126:109862. [PMID: 32120157 DOI: 10.1016/j.biopha.2020.109862] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
94 Wang Q, Ma L, Li J, Yuan C, Sun J, Li K, Qin L, Zang C, Zhao Y, Zhao Y, Zhang Y. A Novel Scoring System for Patients with Recurrence of Hepatocellular Carcinoma After Undergoing Minimal Invasive Therapies. Cancer Manag Res 2019;11:10641-9. [PMID: 31908536 DOI: 10.2147/CMAR.S224711] [Reference Citation Analysis]
95 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
96 Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma 2020;7:117-31. [PMID: 32984089 DOI: 10.2147/JHC.S248314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
97 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
98 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
99 Tampaki M, Savvanis S, Koskinas J. Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues. Ann Gastroenterol 2018;31:670-9. [PMID: 30386116 DOI: 10.20524/aog.2018.0306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
100 Su D, Lin Z. Dichloroacetate attenuates the stemness of hepatocellular carcinoma cells via promoting nucleus-cytoplasm translocation of YAP. Environ Toxicol 2021;36:975-83. [PMID: 33405312 DOI: 10.1002/tox.23098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Vietti Violi N, Fowler KJ, Sirlin CB, Taouli B. Abbreviated Magnetic Resonance Imaging for HCC Surveillance. Clin Liver Dis (Hoboken) 2021;17:133-8. [PMID: 33868653 DOI: 10.1002/cld.1016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Choi GH, Kim G, Choi J, Han S, Lim Y. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [DOI: 10.1111/apt.15311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
103 Shang N, Wang H, Bank T, Perera A, Joyce C, Kuffel G, Zilliox MJ, Cotler SJ, Ding X, Dhanarajan A, Breslin P, Qiu W. Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma. Hepatology 2019;70:1631-45. [PMID: 31069844 DOI: 10.1002/hep.30707] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
104 Sangiovanni A, Colombo M. Bridging to liver transplantation patients with a hepatocellular carcinoma within Milan criteria: how worth is it? Hepatobiliary Surg Nutr 2018;7:202-5. [PMID: 30046574 DOI: 10.21037/hbsn.2018.03.12] [Reference Citation Analysis]
105 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kim BK, Kim DY, Han KH, Seong J. Changes in real-life practice for hepatocellular carcinoma patients in the Republic of Korea over a 12-year period: A nationwide random sample study. PLoS One 2019;14:e0223678. [PMID: 31622424 DOI: 10.1371/journal.pone.0223678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
107 Jia HD, Liang L, Li C, Wu H, Wang H, Liang YJ, Zhou YH, Gu WM, Fan XP, Zhang WG, Chen TH, Chen ZY, Zhong JH, Lau WY, Pawlik TM, Diao YK, Xu QR, Shen F, Zhang CW, Huang DS, Yang T. Long-Term Surgical Outcomes of Liver Resection for Hepatocellular Carcinoma in Patients With HBV and HCV Co-Infection: A Multicenter Observational Study. Front Oncol 2021;11:700228. [PMID: 34395268 DOI: 10.3389/fonc.2021.700228] [Reference Citation Analysis]
108 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
110 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
111 Hernaez R, El-Serag HB. How we approach it: treatment options for hepatocellular carcinoma. Am J Gastroenterol 2018;113:791-4. [PMID: 29713029 DOI: 10.1038/s41395-018-0008-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
112 Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, Brade A, Dinniwell R, Wong RKS, Cho C, Kim TK, Sapisochin G, Dawson LA. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120-126. [PMID: 33285195 DOI: 10.1016/j.radonc.2020.11.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
113 Best J, Bechmann LP, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss KH, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2020;18:728-735.e4. [DOI: 10.1016/j.cgh.2019.11.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 18.5] [Reference Citation Analysis]
114 Li Z, Hu Y, Zeng Q, Wang H, Yan J, Li H, Yu Z. Circular RNA MYLK promotes hepatocellular carcinoma progression by increasing Rab23 expression by sponging miR-362-3p. Cancer Cell Int 2019;19:211. [PMID: 31413665 DOI: 10.1186/s12935-019-0926-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
115 Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int 2021;15:663-75. [PMID: 33877527 DOI: 10.1007/s12072-021-10184-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Sparkman J, Hernaez R, El-Serag HB. Traditional Chinese Medicine to the rescue of allopathic medicine in the co-adjuvant treatment of hepatocellular carcinoma. Transl Gastroenterol Hepatol 2018;3:97. [PMID: 30603733 DOI: 10.21037/tgh.2018.11.05] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
117 Kwee SA, Tiirikainen M, Sato MM, Acoba JD, Wei R, Jia W, Le Marchand L, Wong LL. Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma. Cancer Res 2019;79:1696-704. [PMID: 30760520 DOI: 10.1158/0008-5472.CAN-18-3837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
118 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
119 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology. 2021;73:661-673. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
120 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
121 Yu S, Cai L, Liu C, Gu R, Cai L, Zhuo L. Identification of prognostic alternative splicing events related to the immune microenvironment of hepatocellular carcinoma. Mol Med 2021;27:36. [PMID: 33832428 DOI: 10.1186/s10020-021-00294-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Dai HT, Chen B, Tang KY, Zhang GY, Wen CY, Xiang XH, Yang JY, Guo Y, Lin R, Huang YH. Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Gastrointest Oncol 2021;12:1141-51. [PMID: 34295563 DOI: 10.21037/jgo-21-226] [Reference Citation Analysis]
123 Kim DW, Choi SH, Lee JS, Kim SY, Lee SJ, Byun JH. Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:237. [PMID: 33557040 DOI: 10.3390/diagnostics11020237] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Takamoto T, Makuuchi M. Precision surgery for primary liver cancer. Cancer Biol Med 2019;16:475-85. [PMID: 31565478 DOI: 10.20892/j.issn.2095-3941.2019.0194] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Xu Y, Zhang Z, Xu D, Yang X, Zhou L, Zhu Y. Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma. Cancer Cell Int 2021;21:409. [PMID: 34344378 DOI: 10.1186/s12935-021-02108-2] [Reference Citation Analysis]
127 Xu M, Zhu S, Xu R, Lin N. Identification of CELSR2 as a novel prognostic biomarker for hepatocellular carcinoma. BMC Cancer 2020;20:313. [PMID: 32293343 DOI: 10.1186/s12885-020-06813-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Alqahtani SA, Colombo M. Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approach. Ann Transl Med 2020;8:1255. [PMID: 33178787 DOI: 10.21037/atm-2020-79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
129 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
130 Hafeez Bhatti AB, Qureshi AI, Tahir R, Almas T, Rana A. Liver transplantation for hepatocellular carcinoma: Improving eligibility without compromising outcomes. Ann Med Surg (Lond) 2021;68:102552. [PMID: 34295467 DOI: 10.1016/j.amsu.2021.102552] [Reference Citation Analysis]
131 Gu Y, Li X, Bi Y, Zheng Y, Wang J, Li X, Huang Z, Chen L, Huang Y, Huang Y. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging (Albany NY) 2020;12:784-807. [PMID: 31927532 DOI: 10.18632/aging.102656] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 10.5] [Reference Citation Analysis]
132 Lange N, Dufour JF. Changing Epidemiology of HCC: How to Screen and Identify Patients at Risk? Dig Dis Sci 2019;64:903-9. [PMID: 30863952 DOI: 10.1007/s10620-019-05515-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
133 Liu J, Li Z, Zhang W, Lu H, Sun Z, Wang G, Han X. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients. Front Pharmacol 2021;12:709060. [PMID: 34733154 DOI: 10.3389/fphar.2021.709060] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, Kim KW, Lee SS. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Korean J Radiol 2020;21:280-9. [PMID: 32090520 DOI: 10.3348/kjr.2019.0447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Li Z, Zheng B, Qiu X, Wu R, Wu T, Yang S, Zhu Y, Wu X, Wang S, Gu Z, Shen S, Wu M, Wang H, Chen L. The identification and functional analysis of CD8+PD-1+CD161+ T cells in hepatocellular carcinoma. NPJ Precis Oncol 2020;4:28. [PMID: 33145436 DOI: 10.1038/s41698-020-00133-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
136 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
137 Zeng F, Zhang Y, Han X, Zeng M, Gao Y, Weng J. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns. Front Immunol 2020;11:609900. [PMID: 33574818 DOI: 10.3389/fimmu.2020.609900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, Lubel JS, Kronborg I, Arachchi N, Ryan M, Kemp WW, Knight V, Sundararajan V, Desmond P, Thompson AJ, Bell SJ. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust 2018;209:348-54. [PMID: 30309301 DOI: 10.5694/mja18.00373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
139 Yang X, Hu Y, Yang K, Wang D, Lin J, Long J, Xie F, Mao J, Bian J, Guan M, Pan J, Huo L, Hu K, Yang X, Mao Y, Sang X, Zhang J, Wang X, Zhang H, Zhao H. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e001942. [PMID: 33972389 DOI: 10.1136/jitc-2020-001942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci 2020;21:E4906. [PMID: 32664553 DOI: 10.3390/ijms21144906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
141 Gatti P, Giorgio A, Ciracì E, Roberto I, Anglani A, Sergio S, Rizzello F, Giorgio V, Semeraro S. Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. J Ultrasound 2019;22:363-70. [PMID: 30864004 DOI: 10.1007/s40477-019-00361-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
142 Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DW, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Makowsky M, Negro A, Kudo M, Abou-Alfa GK. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. J Clin Oncol 2021;:JCO2003555. [PMID: 34292792 DOI: 10.1200/JCO.20.03555] [Reference Citation Analysis]
143 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
144 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
145 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
146 Soong RS, Anchoori RK, Roden RBS, Cho RL, Chen YC, Tseng SC, Huang YL, Liao PC, Shyu YC. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling. BMC Cancer 2020;20:386. [PMID: 32375699 DOI: 10.1186/s12885-020-06896-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
147 Galati G, Muley M, Viganò M, Iavarone M, Vitale A, Dell'Unto C, Lai Q, Cabibbo G, Sacco R, Villa E, Trevisani F. Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection: literature review and risk analysis. Expert Opin Drug Saf 2019;18:603-10. [PMID: 31067134 DOI: 10.1080/14740338.2019.1617272] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
148 Lin CY, Lin CC, Wang CC, Chen CL, Hu TH, Hung CH, Huang PY, Tsai MC. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection. World J Surg. 2020;44:247-257. [PMID: 31559485 DOI: 10.1007/s00268-019-05197-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
149 Kielar AZ, Chernyak V, Bashir MR, Do RK, Fowler KJ, Santillan C, Sirlin CB, Mitchell DG, Cerny M, Tang A, Elsayes KM, Kamaya A, Kono Y, Arora SS. An update for LI‐RADS: Version 2018. Why so soon after version 2017? J Magn Reson Imaging 2019;50:1990-1. [DOI: 10.1002/jmri.26715] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
150 Bhatti ABH, Waheed A, Khan NA. Living Donor Liver Transplantation for Hepatocellular Carcinoma: Appraisal of the United Network for Organ Sharing Modified TNM Staging. Front Surg 2020;7:622170. [PMID: 33553240 DOI: 10.3389/fsurg.2020.622170] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
152 Mendiratta-Lala M, Aslam A, Maturen KE, Westerhoff M, Sun Y, Maurino C, Parikh ND, Sonnenday CJ, Stein EB, Shampain KL, Kaza RK, Cuneo K, Masch W, Do RKG, Lawrence TS, Owen D. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02902-3. [PMID: 34644607 DOI: 10.1016/j.ijrobp.2021.10.006] [Reference Citation Analysis]
153 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 19.0] [Reference Citation Analysis]
154 Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ. Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00866-1. [PMID: 34391922 DOI: 10.1016/j.cgh.2021.08.010] [Reference Citation Analysis]
155 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
156 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
157 Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol 2021;27:64-72. [PMID: 33723094 DOI: 10.4103/sjg.sjg_636_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
158 Sagar VM, Herring K, Curbishley S, Hodson J, Fletcher P, Karkhanis S, Mehrzad H, Punia P, Shah T, Shetty S, Ma YT. The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. Oncotarget 2021;12:2338-50. [PMID: 34853657 DOI: 10.18632/oncotarget.28136] [Reference Citation Analysis]
159 Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, La Mura V, Colombo M, Lampertico P. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. Liver Int 2018;38:1624-34. [DOI: 10.1111/liv.13888] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
160 Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med 2021;62:1235-41. [PMID: 33509970 DOI: 10.2967/jnumed.120.257915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Dong Y, Wang QM, Li Q, Li LY, Zhang Q, Yao Z, Dai M, Yu J, Wang WP. Preoperative Prediction of Microvascular Invasion of Hepatocellular Carcinoma: Radiomics Algorithm Based on Ultrasound Original Radio Frequency Signals. Front Oncol 2019;9:1203. [PMID: 31799183 DOI: 10.3389/fonc.2019.01203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Kemp L, Clare KE, Brennan PN, Dillon JF. New horizons in hepatitis B and C in the older adult. Age Ageing 2019;48:32-7. [PMID: 30379991 DOI: 10.1093/ageing/afy170] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Diniz PHC, Silva SDDC, Faria LC, Vidigal PVT, Ferrari TCA. Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics (Sao Paulo) 2020;75:e1529. [PMID: 32520221 DOI: 10.6061/clinics/2020/e1529] [Reference Citation Analysis]
164 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
165 Maesaka K, Sakamori R, Yamada R, Tahata Y, Urabe A, Shigekawa M, Kodama T, Hikita H, Tatsumi T, Takehara T. Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma. Hepatol Res 2020;50:365-73. [PMID: 31661722 DOI: 10.1111/hepr.13446] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
166 Hsu Y, Jun T, Huang Y, Yeh M, Lee C, Ogawa S, Cho S, Lin J, Yu M, Nguyen MH, Tanaka Y. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:1128-37. [DOI: 10.1111/apt.15006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
167 Maheux A, Purcell Y, Harguem S, Vilgrain V, Ronot M. Targeted and non-targeted liver biopsies carry the same risk of complication. Eur Radiol 2019;29:5772-83. [DOI: 10.1007/s00330-019-06227-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, Kang B, Kang MJ, Kim I, Cheon J, Hwang JE, Kang JH, Byeon S, Hong JY, Ryoo BY, Lim HY, Yoo C. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020;40:2544-2552. [PMID: 32563213 DOI: 10.1111/liv.14573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
169 Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol. [DOI: 10.1007/s00261-021-03403-2] [Reference Citation Analysis]
170 Liu C, Yang S, Wang K, Bao X, Liu Y, Zhou S, Liu H, Qiu Y, Wang T, Yu H. Alkaloids from Traditional Chinese Medicine against hepatocellular carcinoma. Biomed Pharmacother 2019;120:109543. [PMID: 31655311 DOI: 10.1016/j.biopha.2019.109543] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
171 Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, Kay CS, Heo SJ, Won JY, Seong J. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121-129. [PMID: 32165253 DOI: 10.1016/j.jhep.2020.03.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 18.5] [Reference Citation Analysis]
172 Mullath A, Krishna M. Hepatocellular carcinoma – time to take the ticket. World J Gastrointest Surg 2019; 11(6): 287-295 [PMID: 31367276 DOI: 10.4240/wjgs.v11.i6.287] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
173 An C, Kim DY, Choi JY, Han KH, Roh YH, Kim MJ. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915. [PMID: 30249190 DOI: 10.1186/s12885-018-4827-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
174 Zhang L, Wu L, Chen Q, Zhang B, Liu J, Liu S, Mo X, Li M, Chen Z, Chen L, You J, Jin Z, Chen X, Zhou Z, Zhang S. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy. EClinicalMedicine 2021;31:100673. [PMID: 33554079 DOI: 10.1016/j.eclinm.2020.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
175 Ye J, Huang G, Zhang X, Xu M, Zhou X, Lin M, Xie X, Xie X. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. International Journal of Hyperthermia 2019;36:55-64. [DOI: 10.1080/02656736.2018.1530460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
176 Min JH, Kim JM, Kim YK, Kim H, Cha DI, Kang TW, Choi GS, Choi SY, Ahn S. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 2021. [PMID: 34242468 DOI: 10.1111/liv.15012] [Reference Citation Analysis]
177 Zhang Y, Zhang MW, Fan XX, Mao DF, Ding QH, Zhuang LH, Lv SY. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(8): 355-368 [PMID: 32903981 DOI: 10.4240/wjgs.v12.i8.355] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Huang DQ, Nguyen MH. Cost-effectiveness of HCC surveillance among HCV patients after sustained virological response with direct-acting antivirals. Liver Int 2021;41:3036-7. [PMID: 34587343 DOI: 10.1111/liv.15072] [Reference Citation Analysis]
179 Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, Yu ML, Chuang WL. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. Kaohsiung J Med Sci 2021;37:145-53. [PMID: 33022892 DOI: 10.1002/kjm2.12303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Sung PS, Choi MH, Yang H, Lee SK, Chun HJ, Jang JW, Choi JY, Yoon SK, Choi JI, Lee YJ, Bae SH. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Front Oncol 2020;10:600233. [PMID: 33330098 DOI: 10.3389/fonc.2020.600233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH, Yu ML. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers (Basel) 2021;13:3455. [PMID: 34298669 DOI: 10.3390/cancers13143455] [Reference Citation Analysis]
182 Wei J, Cui W, Fan W, Wang Y, Li J. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol 2020;10:1285. [PMID: 32850395 DOI: 10.3389/fonc.2020.01285] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
183 Kang HJ, Lee JM, Yoon JH, Han JK. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. Korean J Radiol 2021;22:354-65. [PMID: 33236540 DOI: 10.3348/kjr.2020.0973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
184 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J. Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic. Journal of Gastroenterology and Hepatology 2018;34:1066-73. [DOI: 10.1111/jgh.14564] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
185 Vilar-Gomez E, Lou Z, Kong N, Vuppalanchi R, Imperiale TF, Chalasani N. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System. Clin Gastroenterol Hepatol 2020;18:2305-2314.e12. [PMID: 32289535 DOI: 10.1016/j.cgh.2020.04.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
186 Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Sci Rep. 2020;10:13021. [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
187 Tao Y, Li Y, Liu X, Deng Q, Yu Y, Yang Z. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:2695-2709. [PMID: 30147368 DOI: 10.2147/cmar.s167560] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
188 Wang H, Qian Y, Wu M, Cong W. Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg 2020;24:2737-47. [DOI: 10.1007/s11605-019-04251-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
189 Caraiani C, Boca B, Bura V, Sparchez Z, Dong Y, Dietrich C. CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together? Biology (Basel) 2021;10:412. [PMID: 34066607 DOI: 10.3390/biology10050412] [Reference Citation Analysis]
190 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. J Hep Reports. 2019;1:114-119. [PMID: 32039359 DOI: 10.1016/j.jhepr.2019.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
192 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
193 Ohira M, Tanimine N, Kobayashi T, Ohdan H. Essential updates 2018/2019: Liver transplantation. Ann Gastroenterol Surg 2020;4:195-207. [PMID: 32490333 DOI: 10.1002/ags3.12321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
194 Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Ann Hepatol 2021;21:100225. [PMID: 32687878 DOI: 10.1016/j.aohep.2020.05.007] [Reference Citation Analysis]
195 Galia M, Agnello F, Sparacia G, Matranga D, Albano D, Midiri M, Lagalla R. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. Radiol Med 2018;123:489-97. [PMID: 29546493 DOI: 10.1007/s11547-018-0873-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
196 Shiha G, Soliman R, Mikhail N, Hassan A, Eslam M. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. Liver Int 2021. [PMID: 34174150 DOI: 10.1111/liv.14995] [Reference Citation Analysis]
197 Mueller C, Waldburger N, Stampfl U, Kauczor H, Schirmacher P, Sommer CM, Longerich T. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut 2018;67:991-3. [DOI: 10.1136/gutjnl-2017-314981] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
198 Lin X, Yosaatmadja Y, Kalyukina M, Middleditch MJ, Zhang Z, Lu X, Ding K, Patterson AV, Smaill JB, Squire CJ. Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4. ACS Med Chem Lett 2019;10:1180-6. [PMID: 31413803 DOI: 10.1021/acsmedchemlett.9b00196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
199 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
200 Chen J, Chen YJ, Jiang N, Xu JL, Liang ZM, Bai MJ, Xing YF, Liu Z, Wu XY, Li X. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. Oncologist 2021;26:e1434-44. [PMID: 33675070 DOI: 10.1002/onco.13743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
202 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Zang C, Zhao Y, Qin L, Liu G, Sun J, Li K, Zhao Y, Sheng S, Zhang H, He N, Zhao P, Wang Q, Li X, Peng Y, Dong T, Zhang Y. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages. BMC Cancer 2021;21:1007. [PMID: 34496797 DOI: 10.1186/s12885-021-08720-9] [Reference Citation Analysis]
204 Lai Q, Vitale A, Iesari S, Finkenstedt A, Mennini G, Onali S, Hoppe-Lotichius M, Manzia TM, Nicolini D, Avolio AW, Mrzljak A, Kocman B, Agnes S, Vivarelli M, Tisone G, Otto G, Tsochatzis E, Rossi M, Viveiros A, Ciccarelli O, Cillo U, Lerut J;  European Hepatocellular Cancer Liver Transplant Study Group. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation. Liver Transpl. 2019;25:1023-1033. [PMID: 31087772 DOI: 10.1002/lt.25492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
205 Vernuccio F, Porrello G, Cannella R, Vernuccio L, Midiri M, Giannitrapani L, Soresi M, Brancatelli G. Benign and malignant mimickers of infiltrative hepatocellular carcinoma: tips and tricks for differential diagnosis on CT and MRI. Clin Imaging 2021;70:33-45. [PMID: 33120287 DOI: 10.1016/j.clinimag.2020.10.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
207 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
208 Ichikawa S, Motosugi U, Enomoto N, Onishi H. Magnetic resonance elastography can predict development of hepatocellular carcinoma with longitudinally acquired two-point data. Eur Radiol 2019;29:1013-21. [DOI: 10.1007/s00330-018-5640-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
209 Sun J, Guo Y, Bie B, Zhu M, Tian H, Tian J, Li J, Yang Y, Ji F, Kong G, Li Z. Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway. J Cell Biochem. 2019; Epub ahead of print. [PMID: 31231887 DOI: 10.1002/jcb.29206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
210 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
211 Ismael MN, Forde J, Milla E, Khan W, Cabrera R. Utility of Inflammatory Markers in Predicting Hepatocellular Carcinoma Survival after Liver Transplantation. Biomed Res Int 2019;2019:7284040. [PMID: 31737675 DOI: 10.1155/2019/7284040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
212 Krause J, von Felden J, Casar C, Fründt TW, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann SA, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse AW, Wege H, Schulze K. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype. BMC Cancer 2020;20:1130. [PMID: 33225916 DOI: 10.1186/s12885-020-07580-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
213 Ryu T, Takami Y, Wada Y, Sasaki S, Imamura H, Ureshino H, Saitsu H. Combined hepatectomy and microwave ablation for multifocal hepatocellular carcinoma: Long-term outcomes and prognostic factors. Asian J Surg 2021;44:186-91. [PMID: 32473893 DOI: 10.1016/j.asjsur.2020.05.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Ding J, Wang D, Zhou Y, Zhao L, Zhou H, Jing X, Wang Y. A novel mono-modality fusion imaging method based on three-dimensional contrast-enhanced ultrasound for the evaluation of ablation margins after microwave ablation of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:184-95. [PMID: 33708435 DOI: 10.21037/jgo-21-46] [Reference Citation Analysis]
215 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Zhu J, Fang P, Wang C, Gu M, Pan B, Guo W, Yang X, Wang B. The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:7977-87. [PMID: 34605616 DOI: 10.1002/cam4.4312] [Reference Citation Analysis]
217 Chalasani NP, Ramasubramanian TS, Bhattacharya A, Olson MC, Edwards V DK, Roberts LR, Kisiel JB, Reddy KR, Lidgard GP, Johnson SC, Bruinsma JJ. A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020;. [PMID: 32889146 DOI: 10.1016/j.cgh.2020.08.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
218 Yasui Y, Kurosaki M, Komiyama Y, Takada H, Tamaki N, Watakabe K, Okada M, Wang W, Shimizu T, Kubota Y, Higuchi M, Takaura K, Tsuchiya K, Nakanishi H, Takahashi Y, Itakura J, Enomoto N, Izumi N. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol Res 2018;48:1131-9. [PMID: 30030872 DOI: 10.1111/hepr.13233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
219 Zhu J, Huang Y, Zhang J, Feng Y, Shen L. Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on "Unification of Medicines and Excipients". Drug Des Devel Ther 2020;14:1481-91. [PMID: 32368009 DOI: 10.2147/DDDT.S236997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
220 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Reference Citation Analysis]
221 Acharya SK, Bopanna S. Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different? J Clin Exp Hepatol 2020;10:518-24. [PMID: 33029058 DOI: 10.1016/j.jceh.2020.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Li C, Xin Z, He L, Ning J, Lin K, Pan J, Rao J, Wang G, Zhu H. cFUT8 promotes liver cancer progression by miR-548c/FUT8 axis. Signal Transduct Target Ther 2021;6:30. [PMID: 33500381 DOI: 10.1038/s41392-020-00393-3] [Reference Citation Analysis]
223 Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Reference Citation Analysis]
224 Hu K, Lu S, Li M, Zhang F, Tang B, Yuan J, Shan Y, Xu P, Chen R, Ren Z, Yin X. A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma. J Cancer. 2020;11:4589-4596. [PMID: 32489476 DOI: 10.7150/jca.44847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Sung PS, Jang JW. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. Int J Mol Sci. 2018;19:3648. [PMID: 30463262 DOI: 10.3390/ijms19113648] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
227 Sun X, Hu D, Zhang Y, Lyu N, Xu L, Chen Q, Lai J, Chen M, Zhao M. Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients? J Hepatocell Carcinoma 2020;7:377-84. [PMID: 33365285 DOI: 10.2147/JHC.S287641] [Reference Citation Analysis]
228 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J 2021. [PMID: 34918471 DOI: 10.1002/ueg2.12188] [Reference Citation Analysis]
229 Lin C, Kao J. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:5-14. [DOI: 10.1111/apt.14683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
230 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
231 Chen L, Zhou Q, Liu J, Zhang W. CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma. Front Immunol 2021;12:759565. [PMID: 34777372 DOI: 10.3389/fimmu.2021.759565] [Reference Citation Analysis]
232 Bae JS, Lee JM, Yoon JH, Kang HJ, Jeon SK, Joo I, Lee KB, Kim H. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI. Radiology 2021;299:336-45. [PMID: 33650901 DOI: 10.1148/radiol.2021203537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
235 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
236 Ruiz E, Pineau P, Flores C, Fernández R, Cano L, Cerapio JP, Casavilca-Zambrano S, Berrospi F, Chávez I, Roche B, Bertani S. A preoperative nomogram for predicting long-term survival after resection of large hepatocellular carcinoma (>10 cm). HPB (Oxford) 2021:S1365-182X(21)00177-5. [PMID: 34226129 DOI: 10.1016/j.hpb.2021.06.006] [Reference Citation Analysis]
237 Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81-87. [PMID: 30773192 DOI: 10.1016/j.radonc.2018.12.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
238 Sheen H, Kim JS, Lee JK, Choi SY, Baek SY, Kim JY. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdom Radiol (NY) 2021;46:2839-49. [PMID: 33388805 DOI: 10.1007/s00261-020-02884-x] [Reference Citation Analysis]
239 Yuan W, Tao R, Huang D, Yan W, Shen G, Ning Q. Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. Aging (Albany NY) 2021;13:3969-93. [PMID: 33495404 DOI: 10.18632/aging.202365] [Reference Citation Analysis]
240 Nakamura H, Tanaka S, Miyanishi K, Kawano Y, Osuga T, Ishikawa K, Yoshida M, Ohnuma H, Murase K, Takada K, Yamaguchi H, Nagayama M, Kimura Y, Takemasa I, Kato J. A case of hypervascular tumors in the liver and pancreas: synchronous hepatocellular carcinoma and pancreatic metastasis from renal cell carcinoma 36 years after nephrectomy.Clin Case Rep. 2021;9:932-937. [PMID: 33598275 DOI: 10.1002/ccr3.3691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
241 Zhang DY, Lei JS, Sun WL, Wang DD, Lu Z. Follistatin Like 5 (FSTL5) inhibits epithelial to mesenchymal transition in hepatocellular carcinoma. Chin Med J (Engl) 2020;133:1798-804. [PMID: 32740091 DOI: 10.1097/CM9.0000000000000847] [Reference Citation Analysis]
242 O'Sullivan S, Cagney DN. The emerging role of stereotactic radiotherapy in gastrointestinal malignancies: a review of the literature and analysis from the Irish perspective. Ir J Med Sci 2018;187:887-94. [PMID: 29423821 DOI: 10.1007/s11845-018-1755-8] [Reference Citation Analysis]
243 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
244 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
245 Romano J, Forster E. Hepatocellular Carcinoma in a Patient With Hepatic Steatosis. ACG Case Rep J 2020;7:e00378. [PMID: 32607378 DOI: 10.14309/crj.0000000000000378] [Reference Citation Analysis]
246 Lee SM, Lee JM, Ahn SJ, Kang H, Yang HK, Yoon JH. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium–enhanced MRI. Radiology 2019;292:655-63. [DOI: 10.1148/radiol.2019182867] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
247 Shi F, Zhou Z, Huang X, Liu Q, Lin A. Is anatomical resection necessary for early hepatocellular carcinoma? A single institution retrospective experience. Future Oncology 2019;15:2041-51. [DOI: 10.2217/fon-2019-0117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
248 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
249 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
250 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Kim YH, Jeong DC, Pak K, Han ME, Kim JY, Liangwen L, Kim HJ, Kim TW, Kim TH, Hyun DW, Oh SO. SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget 2017;8:68381-92. [PMID: 28978124 DOI: 10.18632/oncotarget.20266] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
252 Gkika E, Tanadini-lang S, Kirste S, Holzner PA, Neeff HP, Rischke HC, Reese T, Lohaus F, Duma MN, Dieckmann K, Semrau R, Stockinger M, Imhoff D, Kremers N, Häfner MF, Andratschke N, Nestle U, Grosu AL, Guckenberger M, Brunner TB. Interobserver variability in target volume delineation of hepatocellular carcinoma: An analysis of the working group “Stereotactic Radiotherapy” of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 2017;193:823-30. [DOI: 10.1007/s00066-017-1177-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
253 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
254 Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS One 2018;13:e0204412. [PMID: 30260995 DOI: 10.1371/journal.pone.0204412] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
255 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Reference Citation Analysis]
256 Qiu T, Yang J, Pan T, Peng C, Jiang H, Luo Y. Assessment of liver function reserve by photoacoustic tomography: a feasibility study. Biomed Opt Express 2020;11:3985-95. [PMID: 33014580 DOI: 10.1364/BOE.394344] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
257 Lee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on Platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: A nationwide cohort study. PLoS One 2019;14:e0216173. [PMID: 31048923 DOI: 10.1371/journal.pone.0216173] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
258 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Kwak BJ, Park J, Kwon YK, Kwon JH, Yoon YC. Intraoperative radiofrequency ablation and distilled water peritoneal lavage for spontaneously ruptured hepatocellular carcinoma. Ann Surg Treat Res 2019;97:291-5. [PMID: 31824883 DOI: 10.4174/astr.2019.97.6.291] [Reference Citation Analysis]
260 Vo Quang E, Shimakawa Y, Nahon P. Epidemiological projections of viral-induced hepatocellular carcinoma in the perspective of WHO global hepatitis elimination. Liver Int 2021;41:915-27. [PMID: 33641230 DOI: 10.1111/liv.14843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
263 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Reference Citation Analysis]
264 Nguyen N, Rode A, Trillaud H, Aubé C, Manichon AF, Hocquelet A, Paisant A, Dao T, Nahon P, Ganne-Carrié N, Blaise L, Cauchy F, Sutter O, Séror O, Nault JC. Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. Liver Int 2021. [PMID: 34894060 DOI: 10.1111/liv.15129] [Reference Citation Analysis]
265 Li Q, Fan B, Ding J, Xiang X, Zhang J. A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e26948. [PMID: 34414957 DOI: 10.1097/MD.0000000000026948] [Reference Citation Analysis]
266 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
267 Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020;29:189-96. [PMID: 32623383 DOI: 10.3233/CBM-190118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
268 Sempokuya T, Wong LL. Ten-year survival and recurrence of hepatocellular cancer. Hepatoma Res 2019;5:38. [PMID: 31701016 DOI: 10.20517/2394-5079.2019.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
269 Maeda T, Kanzaki H, Chiba T, Ao J, Kanayama K, Maruta S, Kusakabe Y, Saito T, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Nakagawa R, Muroyama R, Kanda T, Maruyama H, Kato N. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma. BMC Cancer. 2019;19:1088. [PMID: 31718608 DOI: 10.1186/s12885-019-6322-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
270 Tsai MY, Yen YH, Huang PY, Sou FM, Lin CC, Cho WR, Wang HM, Chen DW, Chang KC, Wu CK, Hu TH, Tsai MC. The Pre- and Postoperative FIB-4 Indexes Are Good Predictors to the Outcomes of HBV-Related HCC Patients after Resection. Gastroenterol Res Pract 2019;2019:8945798. [PMID: 31885547 DOI: 10.1155/2019/8945798] [Reference Citation Analysis]
271 Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, Giannini EG, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. Journal of Hepatology 2020;73:593-602. [DOI: 10.1016/j.jhep.2020.03.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
273 Wei CY, Chau GY, Chen PH, Liu CA, Huang YH, Huo TI, Hou MC, Lin HC, Su YH, Wu JC, Su CW. A comparison of prognoses between surgical resection and radiofrequency ablation therapy for patients with hepatocellular carcinoma and esophagogastric varices. Sci Rep 2020;10:17259. [PMID: 33057213 DOI: 10.1038/s41598-020-74424-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
274 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
275 Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, Sessagesimi E, Piscaglia F, D'Errico A, Bolondi L, Golfieri R. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018;67:1674-82. [PMID: 29437912 DOI: 10.1136/gutjnl-2017-315384] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 16.0] [Reference Citation Analysis]
276 Mähringer-Kunz A, Meyer FI, Hahn F, Müller L, Düber C, Pinto Dos Santos D, Galle PR, Weinmann A, Kloeckner R, Schotten S. Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. United European Gastroenterol J 2021;9:590-7. [PMID: 34077613 DOI: 10.1002/ueg2.12098] [Reference Citation Analysis]
277 Hu ZQ, Zhou ZJ, Luo CB, Xin HY, Li J, Yu SY, Zhou SL. Peritumoral plasmacytoid dendritic cells predict a poor prognosis for intrahepatic cholangiocarcinoma after curative resection. Cancer Cell Int 2020;20:582. [PMID: 33292317 DOI: 10.1186/s12935-020-01676-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Zhang Y, Chen H, Chen S, Li W. Prognostic value of liver stiffness measurement in patients with hepatocellular carcinoma (HCC) treated by radiofrequency ablation: a meta-analysis. Int J Hyperthermia 2021;38:1052-9. [PMID: 34251953 DOI: 10.1080/02656736.2021.1947529] [Reference Citation Analysis]
279 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
280 Yoh T, Seo S, Taura K, Hamaguchi Y, Ogiso S, Fukumitsu K, Ishii T, Hata K, Kaido T, Nakamoto Y, Uemoto S. Identifying Patients Who May Benefit from Liver Resection Compared to Living Donor Liver Transplantation for Hepatocellular Carcinoma Using 18F-FDG PET. World J Surg 2021. [PMID: 34274984 DOI: 10.1007/s00268-021-06235-9] [Reference Citation Analysis]
281 Fouad R, Elsharkawy A, Abdel Alem S, El Kassas M, Alboraie M, Sweedy A, Afify S, Abdellatif Z, Khairy M, Esmat G. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. Eur J Gastroenterol Hepatol 2019;31:1129-34. [PMID: 30896550 DOI: 10.1097/MEG.0000000000001400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
282 Shi QM, Xue C, He YT, Hu XB, Yu ZJ. Massive abdominal hemorrhage after radiofrequency ablation of recurrent hepatocellular carcinoma with successful hemostasis achieved through transarterial embolization: a case report. J Int Med Res 2020;48:300060519898012. [PMID: 32046546 DOI: 10.1177/0300060519898012] [Reference Citation Analysis]
283 Tipaldi MA, Ronconi E, Lucertini E, Krokidis M, Zerunian M, Polidori T, Begini P, Marignani M, Mazzuca F, Caruso D, Rossi M, Laghi A. Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features. Diagnostics (Basel) 2021;11:956. [PMID: 34073545 DOI: 10.3390/diagnostics11060956] [Reference Citation Analysis]
284 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
285 Mojtahed A, Núñez L, Connell J, Fichera A, Nicholls R, Barone A, Marieiro M, Puddu A, Arya Z, Ferreira C, Ridgway G, Kelly M, Lamb HJ, Caseiro-Alves F, Brady JM, Banerjee R. Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. Abdom Radiol (NY) 2021. [PMID: 34605963 DOI: 10.1007/s00261-021-03262-x] [Reference Citation Analysis]
286 Liu K, McCaughan GW. How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma. Expert Opin Pharmacother 2018;19:1167-70. [PMID: 30011239 DOI: 10.1080/14656566.2018.1498843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
287 Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
288 Kim M, Lee S, An C. Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma. Eur Radiol 2019;29:5101-10. [DOI: 10.1007/s00330-019-06030-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
289 Lei Y, Yee LW, Zhou WP. Multiple hepatocellular carcinomas: liver resection or transcatheter arterial chemoembolization? Hepatobiliary Surg Nutr 2019;8:519-21. [PMID: 31673544 DOI: 10.21037/hbsn.2019.05.13] [Reference Citation Analysis]
290 Wang XD, Peng JB, Zhou CY, Que Q, Li HY, He Y, Yang H. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles. Oncol Rep 2020;43:1915-27. [PMID: 32186781 DOI: 10.3892/or.2020.7545] [Reference Citation Analysis]
291 Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatol Res 2019;49:919-28. [PMID: 30969006 DOI: 10.1111/hepr.13348] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
292 Koh YX, Tan HJ, Liew YX, Syn N, Teo JY, Lee SY, Goh BKP, Goh GBB, Chan CY. Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma. J Am Coll Surg 2019;229:467-478.e1. [PMID: 31398386 DOI: 10.1016/j.jamcollsurg.2019.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
293 Piñero F, Thompson MA, Diaz Telli F, Trentacoste J, Padín C, Mendizabal M, Colaci C, Gonzalez Campaña A, Pages J, Montal S, Barreiro M, Fauda M, Podestá G, Perotti JP, Silva M. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Ann Hepatol 2020;19:662-7. [PMID: 32683095 DOI: 10.1016/j.aohep.2020.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
294 Tsurugai Y, Takeda A, Sanuki N, Eriguchi T, Ueno M. Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. Cureus 2021;13:e18624. [PMID: 34765376 DOI: 10.7759/cureus.18624] [Reference Citation Analysis]
295 Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know. Semin Intervent Radiol 2021;38:405-11. [PMID: 34629706 DOI: 10.1055/s-0041-1732323] [Reference Citation Analysis]
296 Wang Y, Yang Y, Gao H, Ouyang T, Zhang L, Hu J, Hu S, Kan H. Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma. Front Oncol 2020;10:566183. [PMID: 33665158 DOI: 10.3389/fonc.2020.566183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Zhou B, Yang C, Yan X, Shi Z, Xiao H, Wei X, Jiang N, Wu Z. LETM1 Knockdown Promotes Autophagy and Apoptosis Through AMP-Activated Protein Kinase Phosphorylation-Mediated Beclin-1/Bcl-2 Complex Dissociation in Hepatocellular Carcinoma. Front Oncol 2020;10:606790. [PMID: 33552978 DOI: 10.3389/fonc.2020.606790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
298 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
299 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
300 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Reference Citation Analysis]
301 Qian X, Zhang W, Shams A, Mohammed K, Befeler AS, Kang N, Lai J. Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization. Liver Res 2020;4:212-7. [PMID: 33520338 DOI: 10.1016/j.livres.2020.11.002] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Feng JK, Sun JX, Liu ZH, Gu JW, Chen ZH, Liu C, Guo WX, Shi J, Cheng SQ. Efficacy and Safety of Transarterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma Associated with Bile Duct Tumor Thrombus: A Real-World Retrospective Cohort Study. Cancer Manag Res 2021;13:3551-60. [PMID: 33953609 DOI: 10.2147/CMAR.S307065] [Reference Citation Analysis]
303 Kim JS, Lee JK, Baek SY, Yun HI. Diagnostic performance of a minimized protocol of non-contrast MRI for hepatocellular carcinoma surveillance. Abdom Radiol 2020;45:211-9. [DOI: 10.1007/s00261-019-02277-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
304 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
305 da Fonseca L, Carrilho FJ. Expanding TACTICS trial into a different setting in hepatocellular carcinoma. Ann Hepatol 2020;19:230-1. [PMID: 32139261 DOI: 10.1016/j.aohep.2020.02.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Shen Q, Hu G, Wu J, Lv L. A new clinical prognostic nomogram for liver cancer based on immune score. PLoS One 2020;15:e0236622. [PMID: 32730361 DOI: 10.1371/journal.pone.0236622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
307 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
308 Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatol Res 2019;50:137-43. [DOI: 10.1111/hepr.13416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
309 Beumer BR, Buettner S, Galjart B, van Vugt JLA, de Man RA, IJzermans JNM, Koerkamp BG. Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. Eur J Surg Oncol 2021:S0748-7983(21)00738-1. [PMID: 34602315 DOI: 10.1016/j.ejso.2021.09.012] [Reference Citation Analysis]
310 Czauderna C, Schmidtmann I, Koch S, Pilz L, Heinrich S, Otto G, Mittler J, Lang H, Kloeckner R, Düber C, Sprinzl MF, Worns MA, Galle PR, Marquardt JU, Weinmann A. High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J 2021. [PMID: 33709539 DOI: 10.1177/2050640620972611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
311 Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
312 Orlandi P, Solini A, Banchi M, Brunetto MR, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel) 2021;14:995. [PMID: 34681219 DOI: 10.3390/ph14100995] [Reference Citation Analysis]
313 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
314 Shin SW, Ahn KS, Kim SW, Kim TS, Kim YH, Kang KJ. Liver Resection Versus Local Ablation Therapies for Hepatocellular Carcinoma Within the Milan Criteria: A Systemic Review and Meta-analysis. Ann Surg. 2020;. [PMID: 33074898 DOI: 10.1097/sla.0000000000004350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
315 Erkan B, Meier J, Clark TJ, Kaplan J, Lambert JR, Chang S. Non-invasive diagnostic criteria of hepatocellular carcinoma: Comparison of diagnostic accuracy of updated LI-RADS with clinical practice guidelines of OPTN-UNOS, AASLD, NCCN, EASL-EORTC, and KLSCG-NCC. PLoS One 2019;14:e0226291. [PMID: 31821360 DOI: 10.1371/journal.pone.0226291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
316 Bucalau AM, Tancredi I, Pezzullo M, Covas A, Verset G. Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. Acta Gastroenterol Belg 2021;84:371-4. [PMID: 34217191 DOI: 10.51821/84.2.371] [Reference Citation Analysis]
317 Kim NJ, Jacob DA, Ioannou GN, John BV, Rogal S, Rozenberg-Ben-Dror K. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol 2021;116:411-5. [PMID: 33252455 DOI: 10.14309/ajg.0000000000001000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
318 Salem R, Gabr A, Riaz A, Mora R, Ali R, Abecassis M, Hickey R, Kulik L, Ganger D, Flamm S, Atassi R, Atassi B, Sato K, Benson AB, Mulcahy MF, Abouchaleh N, Asadi AA, Desai K, Thornburg B, Vouche M, Habib A, Caicedo J, Miller FH, Yaghmai V, Kallini JR, Mouli S, Lewandowski RJ. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000‐patient 15‐year experience. Hepatology 2018;68:1429-40. [DOI: 10.1002/hep.29691] [Cited by in Crossref: 87] [Cited by in F6Publishing: 70] [Article Influence: 21.8] [Reference Citation Analysis]
319 Brusset B, Dumortier J, Cherqui D, Pageaux GP, Boleslawski E, Chapron L, Quesada JL, Radenne S, Samuel D, Navarro F, Dharancy S, Decaens T. Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. Cancers (Basel) 2021;13:2480. [PMID: 34069594 DOI: 10.3390/cancers13102480] [Reference Citation Analysis]
320 Brown A, Kachura J. Natural Language Processing of Radiology Reports in Patients With Hepatocellular Carcinoma to Predict Radiology Resource Utilization. Journal of the American College of Radiology 2019;16:840-4. [DOI: 10.1016/j.jacr.2018.12.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
321 Mizukoshi E, Kaneko S. Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol 2019;12:52. [PMID: 31142330 DOI: 10.1186/s13045-019-0742-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
322 Feld JJ, Krassenburg LAP. What Comes First: Treatment of Viral Hepatitis or Liver Cancer? Dig Dis Sci 2019;64:1041-9. [PMID: 30874985 DOI: 10.1007/s10620-019-05518-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
323 Seo N, Kim MJ, Rhee H. Hepatic sarcomatoid carcinoma: magnetic resonance imaging evaluation by using the liver imaging reporting and data system. Eur Radiol 2019;29:3761-71. [PMID: 30859282 DOI: 10.1007/s00330-019-06052-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
324 Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology. 2019;69:1180-1192. [PMID: 30168613 DOI: 10.1002/hep.30244] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
325 Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS One 2020;15:e0231828. [PMID: 32310967 DOI: 10.1371/journal.pone.0231828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
326 Park DJ, Sung PS, Kim JH, Lee GW, Jang JW, Jung ES, Bae SH, Choi JY, Yoon SK. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1. J Immunother Cancer 2020;8:e000301. [PMID: 32221015 DOI: 10.1136/jitc-2019-000301] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
327 Alhasan A, Cerny M, Olivié D, Billiard J, Bergeron C, Brown K, Bodson-clermont P, Castel H, Turcotte S, Perreault P, Tang A. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol 2019;44:517-28. [DOI: 10.1007/s00261-018-1762-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
328 Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity. Hepatol Res 2021. [PMID: 34626450 DOI: 10.1111/hepr.13720] [Reference Citation Analysis]
329 Mehta N, Monto A, Yao FY. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology 2019;156:1215-7. [DOI: 10.1053/j.gastro.2018.09.061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
330 Tang A, Cruite I, Mitchell DG, Sirlin CB. Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 2018;43:3-12. [PMID: 28840293 DOI: 10.1007/s00261-017-1292-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
331 Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [Reference Citation Analysis]
332 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Michel M, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers (Basel) 2021;13:5018. [PMID: 34638502 DOI: 10.3390/cancers13195018] [Reference Citation Analysis]
333 Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci 2021;112:3314-23. [PMID: 34080242 DOI: 10.1111/cas.15004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
334 Liu M, Xu M, Tang T. Association between chemotherapy and prognostic factors of survival in hepatocellular carcinoma: a SEER population-based cohort study. Sci Rep 2021;11:23754. [PMID: 34887446 DOI: 10.1038/s41598-021-02698-x] [Reference Citation Analysis]
335 Yu B, Liang H, Ye Q, Wang Y. Establishment of a Genomic-Clinicopathologic Nomogram for Predicting Early Recurrence of Hepatocellular Carcinoma After R0 Resection. J Gastrointest Surg 2021;25:112-24. [PMID: 32128678 DOI: 10.1007/s11605-020-04554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
336 Rao C, Wang X, Li M, Zhou G, Gu H. Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2020;20:43. [PMID: 32345247 DOI: 10.1186/s12880-020-00433-y] [Reference Citation Analysis]
337 Itri JN, Raghavan K, Patel SB, Broder JC, Tierney S, Gray D, Burleson J, Macdonald S, Seidenwurm DJ. Developing Quality Measures for Diagnostic Radiologists: Part 2. Journal of the American College of Radiology 2018;15:1366-84. [DOI: 10.1016/j.jacr.2018.05.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
338 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
339 Dietrich CF, Shi L, Löwe A, Dong Y, Potthoff A, Sparchez Z, Teufel A, Guth S, Koch J, Barr RG, Cui XW. Conventional ultrasound for diagnosis of hepatic steatosis is better than believed. Z Gastroenterol 2021. [PMID: 34171931 DOI: 10.1055/a-1491-1771] [Reference Citation Analysis]
340 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
341 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, Toyoda H, Kumada T, Goto H, Hirooka Y. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients: Noninvasive fibrosis markers for non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:207-14. [DOI: 10.1111/jgh.14448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
342 Huang JY, Li JW, Lu Q, Luo Y, Lin L, Shi YJ, Li T, Liu JB, Lyshchik A. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma. Radiology. 2020;294:329-339. [PMID: 31793849 DOI: 10.1148/radiol.2019191086] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
343 Lubel JS, Roberts SK, Strasser SI, Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT, Shackel N. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Med J Aust 2021;214:475-83. [PMID: 33314233 DOI: 10.5694/mja2.50885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
344 Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Risk and outcome of hepatocellular carcinoma in liver cirrhosis in Southern Sweden: a population-based study. Scand J Gastroenterol 2019;54:1027-32. [PMID: 31389730 DOI: 10.1080/00365521.2019.1649454] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
345 Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H, Jia J; CR-Hepb Study Group, Beijing, China. China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health 2020;48:233-9. [PMID: 29716439 DOI: 10.1177/1403494818772188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
346 Sorop A, Iacob R, Iacob S, Constantinescu D, Chitoiu L, Fertig TE, Dinischiotu A, Chivu-Economescu M, Bacalbasa N, Savu L, Gheorghe L, Dima S, Popescu I. Plasma Small Extracellular Vesicles Derived miR-21-5p and miR-92a-3p as Potential Biomarkers for Hepatocellular Carcinoma Screening. Front Genet 2020;11:712. [PMID: 32793278 DOI: 10.3389/fgene.2020.00712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
347 Wang JP, Yao ZG, Sun YW, Liu XH, Sun FK, Lin CH, Ren FX, Lv BB, Zhang SJ, Wang Y, Meng FY, Zheng SZ, Gong W, Liu J. Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma. World J Gastroenterol 2020; 26(29): 4327-4342 [PMID: 32848337 DOI: 10.3748/wjg.v26.i29.4327] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
348 Huang G, Yang Y, Lv M, Huang T, Zhan X, Kang W, Hou J. Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:9759-70. [PMID: 33061455 DOI: 10.2147/OTT.S248660] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
349 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
350 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Bhat V, Srinathan S, Pasini E, Angeli M, Chen E, Baciu C, Bhat M. Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis. World J Hepatol 2018; 10(1): 155-165 [PMID: 29399289 DOI: 10.4254/wjh.v10.i1.155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
352 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
353 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
354 Putzer D, Schullian P, Braunwarth E, Fodor M, Primavesi F, Cardini B, Resch T, Oberhuber R, Maglione M, Margreiter C, Schneeberger S, Stättner S, Öfner-Velano D, Jaschke W, Bale RJ. Integrating interventional oncology in the treatment of liver tumors. Eur Surg 2018;50:117-24. [PMID: 29875800 DOI: 10.1007/s10353-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
355 Matsuki Y, Matono T, Koda M, Miyoshi K, Sugihara T, Okano JI, Isomoto H. Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinoma. Eur J Radiol 2020;133:109358. [PMID: 33126170 DOI: 10.1016/j.ejrad.2020.109358] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
356 Wu L, Tsilimigras DI, Farooq A, Hyer JM, Merath K, Paredes AZ, Mehta R, Sahara K, Shen F, Pawlik TM. Management and outcomes among patients with sarcomatoid hepatocellular carcinoma: A population-based analysis. Cancer 2019;125:3767-75. [PMID: 31299092 DOI: 10.1002/cncr.32396] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
357 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
358 Thibodeau-Antonacci A, Petitclerc L, Gilbert G, Bilodeau L, Olivié D, Cerny M, Castel H, Turcotte S, Huet C, Perreault P, Soulez G, Chagnon M, Kadoury S, Tang A. Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magn Reson Imaging 2019;62:78-86. [PMID: 31247250 DOI: 10.1016/j.mri.2019.06.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
359 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers (Basel) 2020;12:E2906. [PMID: 33050527 DOI: 10.3390/cancers12102906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
360 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
361 Chen WM, Wei KL, Tung SY, Shen CH, Chang TS, Yen CW, Hsieh YY, Chiu WN, Hu JH, Lu SN, Hung CH. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy. J Formos Med Assoc 2020;119:1593-600. [PMID: 32839045 DOI: 10.1016/j.jfma.2020.08.010] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
362 Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J Gastroenterol 2018; 24(2): 161-169 [PMID: 29375202 DOI: 10.3748/wjg.v24.i2.161] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
363 Eldeeb MK, Magour GM, Bedair RN, Shamseya MM, Hammouda MA. Study of Dickkopf-1 (DKK-1) in patients with chronic viral hepatitis C-related liver cirrhosis with and without hepatocellular carcinoma. Clin Exp Hepatol 2020;6:85-91. [PMID: 32728624 DOI: 10.5114/ceh.2020.95831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
364 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
365 Christou CD, Tooulias A, Tsolakidis A, Papayiannis V, Pianetcki-Tsiantzi B, Tsoulfas G, Papadopoulos VN. Management of Hepatocellular Carcinoma in the Era of Individualized Therapy: The Experience of a Greek Tertiary Center.Ochsner J. 2020;20:272-278. [PMID: 33071659 DOI: 10.31486/toj.19.0092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
366 Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, Toyoda H, Kumada T, Fujishiro M. Serum Nutritional Markers as Prognostic Factors for Hepatic and Extrahepatic Carcinogenesis in Japanese Patients with Nonalcoholic Fatty Liver Disease. Nutr Cancer 2020;72:884-91. [PMID: 31433263 DOI: 10.1080/01635581.2019.1653474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
367 Cao S, Zou Y, Lyu T, Fan Z, Guan H, Song L, Tong X, Wang J. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression. Int J Hyperthermia 2022;39:1-7. [PMID: 34937501 DOI: 10.1080/02656736.2021.1998660] [Reference Citation Analysis]
368 Patkar S, Parray A, Mahendra B, Kurunkar S, Goel M. Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study. J Surg Oncol 2019;120:1119-25. [PMID: 31549392 DOI: 10.1002/jso.25704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
369 Huang K, Xie W, Wang S, Li Q, Wei X, Chen B, Hua Y, Li S, Peng B, Shen S. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma. J Invest Surg 2021;34:1011-20. [PMID: 32066292 DOI: 10.1080/08941939.2020.1728443] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
370 Costentin CE, Nahon P. HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor? JHEP Rep 2021;3:100320. [PMID: 34308325 DOI: 10.1016/j.jhepr.2021.100320] [Reference Citation Analysis]
371 Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, Gawrieh S, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. Am J Gastroenterol 2020;115:1486-95. [PMID: 32453046 DOI: 10.14309/ajg.0000000000000643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
372 Bartolotta TV, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. Insights Imaging. 2020;11:9. [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
373 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 28.3] [Reference Citation Analysis]
374 Wang Z, Fan Q, Wang M, Wang E, Li H, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patients treated with the combination therapy of transarterial chemoembolization and sorafenib for hepatocellular carcinoma. Ann Transl Med 2020;8:537. [PMID: 32411760 DOI: 10.21037/atm.2020.02.114] [Reference Citation Analysis]
375 Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis. Hepatology 2021;73:713-25. [PMID: 32383272 DOI: 10.1002/hep.31309] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
376 Wasnik AP. Tumor Response Criteria—Radiological Implications. Academic Radiology 2018;25:1361-2. [DOI: 10.1016/j.acra.2018.07.011] [Reference Citation Analysis]
377 Son J, Hwang SH, Park S, Han K, Chung YE, Choi J, Kim M, Park M. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. Investigative Radiology 2019;54:494-9. [DOI: 10.1097/rli.0000000000000562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
378 Chen S, Li J, Tan X, Xu Q, Mo Y, Qin H, Zhou L, Ma L, Wei Z. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study. J Clin Lab Anal 2020;34:e23262. [PMID: 32167614 DOI: 10.1002/jcla.23262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
379 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiotherapy and Oncology 2019;133:1-8. [DOI: 10.1016/j.radonc.2018.12.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
380 Moini M, Onofrio F, Hansen BE, Adeyi O, Khalili K, Patel K. Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease. Sci Rep 2021;11:19275. [PMID: 34588540 DOI: 10.1038/s41598-021-98776-1] [Reference Citation Analysis]
381 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int 2020;40:968-76. [DOI: 10.1111/liv.14405] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
382 Heinrich S, Sprinzl M, Schmidtmann I, Heil E, Koch S, Czauderna C, Heinrich B, Philippe P Diggs L, Wörns MA, Kloeckner R, Galle PR, Marquardt JU, Weinmann A. Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. United European Gastroenterol J 2020;8:444-52. [PMID: 32213028 DOI: 10.1177/2050640620904524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
383 Bo XW, Sun LP, Yu SY, Xu HX. Thermal ablation and immunotherapy for hepatocellular carcinoma: Recent advances and future directions. World J Gastrointest Oncol 2021; 13(10): 1397-1411 [PMID: 34721773 DOI: 10.4251/wjgo.v13.i10.1397] [Reference Citation Analysis]
384 Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D'Addeo K, Tate JP, Lim JK, Goetz MB, Rodriguez-Barradas MC, Bräu N, Brown ST, Taddei TH, Justice AC, Lo Re V 3rd. Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma. J Acquir Immune Defic Syndr 2020;85:530-4. [PMID: 33185999 DOI: 10.1097/QAI.0000000000002510] [Reference Citation Analysis]
385 Lin SF, Tung SY, Wei KL, Chen CH, Hu TH, Shen CH, Chang TS, Chen WM, Yen CW, Wang JH, Hung CH, Lu SN. Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C. PLoS One 2020;15:e0229994. [PMID: 32126125 DOI: 10.1371/journal.pone.0229994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
386 Colasanti M, Berardi G, Mariano G, Ferretti S, Meniconi RL, Guglielmo N, Ettorre GM. Laparoscopic Left Hepatectomy for Hepatocellular Carcinoma Recurrence Following Liver Transplantation. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11275-5] [Reference Citation Analysis]
387 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
388 Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
389 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
390 Zhou Q, Tuo F, Li R, Wang X, Wang J, Huang Z, Chen M, Huang J. Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Front Oncol 2020;10:578763. [PMID: 33251141 DOI: 10.3389/fonc.2020.578763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
391 Wang YL, Liu JY, Yang JE, Yu XM, Chen ZL, Chen YJ, Kuang M, Zhu Y, Zhuang SM. Lnc-UCID Promotes G1/S Transition and Hepatoma Growth by Preventing DHX9-Mediated CDK6 Down-regulation. Hepatology 2019;70:259-75. [PMID: 30865310 DOI: 10.1002/hep.30613] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
392 Liu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D. Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics. Front Oncol 2020;10:539692. [PMID: 33072569 DOI: 10.3389/fonc.2020.539692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156:477-491.e1. [PMID: 30367835 DOI: 10.1053/j.gastro.2018.08.065] [Cited by in Crossref: 365] [Cited by in F6Publishing: 367] [Article Influence: 91.3] [Reference Citation Analysis]
394 Wong RJ, Ahmed A; Hepatocellular Carcinoma Research Committee of the Chronic Liver Disease Foundation. Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.J Clin Gastroenterol. 2020;54:850-856. [PMID: 33030855 DOI: 10.1097/MCG.0000000000001422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Schoenberg MB, Ehmer U, Umgelter A, Bucher JN, Koch DT, Börner N, Nieß H, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy - a retrospective observational study. Transpl Int 2021;34:465-73. [PMID: 33368655 DOI: 10.1111/tri.13808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
397 Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15:105-13. [PMID: 33547557 DOI: 10.1007/s12072-020-10124-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
398 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
399 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
400 Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF, Yu ML. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Med 2021. [PMID: 34786871 DOI: 10.1002/cam4.4430] [Reference Citation Analysis]
401 Bhat M, Pasini E, Pastrello C, Rahmati S, Angeli M, Kotlyar M, Ghanekar A, Jurisica I. Integrative analysis of layers of data in hepatocellular carcinoma reveals pathway dependencies. World J Hepatol 2021; 13(1): 94-108 [PMID: 33584989 DOI: 10.4254/wjh.v13.i1.94] [Reference Citation Analysis]
402 Kim AK, Hamilton JP, Lin SY, Chang T, Hann H, Hu C, Lou Y, Lin Y, Gade TP, Park G, Luu H, Lee T, Wang J, Chen D, Goggins MG, Jain S, Song W, Su Y. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. [DOI: 10.1038/s41416-022-01706-9] [Reference Citation Analysis]
403 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 998] [Article Influence: 282.3] [Reference Citation Analysis]
404 Lim J, Singal AG. Surveillance and Diagnosis of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;13:2-5. [PMID: 30911378 DOI: 10.1002/cld.761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
405 Lee J, Lim YS, Lee JH, Gwak GY, Do M, Yeo I, Shin D, Han D, Park T, Kim Y. Inclusive Quantification Assay of Serum Des-γ-Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatol Commun 2021;5:1767-83. [PMID: 34558815 DOI: 10.1002/hep4.1752] [Reference Citation Analysis]
406 Feng Y, Dramani Maman ST, Zhu X, Liu X, Bongolo CC, Liang C, Tu J. Clinical value and potential mechanisms of LINC00221 in hepatocellular carcinoma based on integrated analysis. Epigenomics 2021;13:299-317. [PMID: 33406920 DOI: 10.2217/epi-2020-0363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
407 Lhewa D, Green EW, Naugler WE. Multidisciplinary Team Management of Hepatocellular Carcinoma Is Standard of Care. Clin Liver Dis. 2020;24:771-787. [PMID: 33012458 DOI: 10.1016/j.cld.2020.07.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
408 Dietrich CF, Potthoff A, Helmberger T, Ignee A, Willmann JK; on behalf of the CEUS LI-RADS Working Group. Standardisierte Befundung und Dokumentation der Kontrastmittelsonografie der Leber (CEUS LI-RADS). Z Gastroenterol 2018;56:499-506. [DOI: 10.1055/s-0043-124874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
409 Darnell A, Rimola J, Belmonte E, Ripoll E, Garcia-Criado Á, Caparroz C, Díaz-González Á, Vilana R, Reig M, Ayuso C, Bruix J, Forner A. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. Eur Radiol 2021;31:4794-803. [PMID: 33409789 DOI: 10.1007/s00330-020-07457-6] [Reference Citation Analysis]
410 Lucà MG, Nani R, Schranz M, De Giorgio M, Iegri C, Agazzi R, Sala F, Virotta G, Sarti D, Conte G, Pinelli D, Nicora C, Colledan M, Sironi S, Fagiuoli S. Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib. Future Oncology 2018;14:727-35. [DOI: 10.2217/fon-2017-0566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Liu X, Wen J, Yi H, Hou X, Yin Y, Ye G, Wu X, Jiang X. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. Ther Adv Med Oncol. 2020;12:1758835920910347. [PMID: 32215059 DOI: 10.1177/1758835920910347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
412 Maruyama H, Yamaguchi T, Nagamatsu H, Shiina S. AI-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. Diagnostics (Basel) 2021;11:292. [PMID: 33673229 DOI: 10.3390/diagnostics11020292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
413 Duan T, Jiang H, Xia C, Chen J, Cao L, Ye Z, Wei Y, Song B, Lee JM. Assessing Liver Function in Liver Tumors Patients: The Performance of T1 Mapping and Residual Liver Volume on Gd-EOBDTPA-Enhanced MRI. Front Med (Lausanne) 2020;7:215. [PMID: 32549039 DOI: 10.3389/fmed.2020.00215] [Reference Citation Analysis]
414 Alim A, Karataş C. Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review. J Gastrointest Cancer 2021. [PMID: 34882291 DOI: 10.1007/s12029-021-00730-x] [Reference Citation Analysis]
415 He L, Xia Z, Shen J, Zhang X, Peng W, Li C, Wen T. The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Medicine (Baltimore) 2019;98:e14386. [PMID: 30732177 DOI: 10.1097/MD.0000000000014386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
417 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
418 Ding X, Sun W, Chen J, Li W, Shen Y, Guo X, Teng Y, Liu X, Sun S, Wei J, Li W, Chen H, Liu B. Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study. Front Oncol 2020;10:578633. [PMID: 33194699 DOI: 10.3389/fonc.2020.578633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
419 Xu YJ, Lai ZC, He MK, Bu XY, Chen HW, Zhou YM, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M, Li QJ. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211063848. [PMID: 34898313 DOI: 10.1177/15330338211063848] [Reference Citation Analysis]
420 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
421 Mourad M, Mabrut J, Chellakhi M, Lesurtel M, Prevost C, Ducerf C, Rode A, Merle P, Mornex F, Mohkam K. Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. Future Oncology 2019;15:2517-30. [DOI: 10.2217/fon-2019-0127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
422 Sadeghi S, Bejjani A, Finn RS. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:695-715. [PMID: 31472914 DOI: 10.1016/j.soc.2019.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
423 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
424 Bannaga AS, Kvasnik F, Persaud K, Arasaradnam RP. Differentiating cancer types using a urine test for volatile organic compounds. J Breath Res 2020;15:017102. [PMID: 33086204 DOI: 10.1088/1752-7163/abc36b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
425 Wang H, Jiang W, Wang H, Wei Z, Li H, Yan H, Han P. Identification of Mutation Landscape and Immune Cell Component for Liver Hepatocellular Carcinoma Highlights Potential Therapeutic Targets and Prognostic Markers. Front Genet 2021;12:737965. [PMID: 34603396 DOI: 10.3389/fgene.2021.737965] [Reference Citation Analysis]
426 Ren S, Qi Q, Liu S, Duan S, Mao B, Chang Z, Zhang Y, Wang S, Zhang L. Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: A multicenter study. Eur J Radiol 2021;143:109891. [PMID: 34481117 DOI: 10.1016/j.ejrad.2021.109891] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
427 Xing H, Zheng YJ, Han J, Zhang H, Li ZL, Lau WY, Shen F, Yang T. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: A systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17:487-495. [PMID: 30257796 DOI: 10.1016/j.hbpd.2018.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
428 Liao SH, Chen CL, Hsu CY, Chien KL, Kao JH, Chen PJ, Chen TH, Chen CH. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol 2021;75:132-41. [PMID: 33689789 DOI: 10.1016/j.jhep.2021.02.029] [Reference Citation Analysis]
429 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
430 Mendizabal M, Piñero F, Ridruejo E, Herz Wolff F, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Videla Zuain MG, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, de Araujo A, Varón A, Rubinstein F, Cheinquer H, Silva M. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology 2020;18:2554-2563.e3. [DOI: 10.1016/j.cgh.2020.02.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
431 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
432 Zhuang L, Yang Z, Meng Z. Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients. Biomed Res Int 2018;2018:7897346. [PMID: 30363964 DOI: 10.1155/2018/7897346] [Cited by in Crossref: 39] [Cited by in F6Publishing: 49] [Article Influence: 9.8] [Reference Citation Analysis]
433 Wang Z, Yu XL, Zhang J, Cheng ZG, Han ZY, Liu FY, Dou JP, Kong Y, Dong XJ, Zhao QX, Yu J, Liang P, Tang WZ. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol 2021;281:114539. [PMID: 34428522 DOI: 10.1016/j.jep.2021.114539] [Reference Citation Analysis]
434 Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00318-2. [PMID: 34193367 DOI: 10.1016/j.dld.2021.06.003] [Reference Citation Analysis]
435 Yu C, Song C, Lv J, Zhu M, Yu C, Guo Y, Yang L, Chen Y, Chen Z, Jiang T, Ma H, Jin G, Shen H, Hu Z, Li L; China Kadoorie Biobank Collaborative Group. Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. Int J Cancer 2021;148:2924-34. [PMID: 33521941 DOI: 10.1002/ijc.33487] [Reference Citation Analysis]
436 Lee MH, Thomas JL, Li JA, Chen JR, Wang TL, Lin HY. Synthesis of Multifunctional Nanoparticles for the Combination of Photodynamic Therapy and Immunotherapy. Pharmaceuticals (Basel) 2021;14:508. [PMID: 34073468 DOI: 10.3390/ph14060508] [Reference Citation Analysis]
437 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
438 Cao X, Liu L, Cao X, Cui Y, Zou C, Chen A, Qiu Y, Quan M, Ren K, Chen X, Cao J. The DNMT1/miR-34a/FOXM1 Axis Contributes to Stemness of Liver Cancer Cells. J Oncol 2020;2020:8978930. [PMID: 32308683 DOI: 10.1155/2020/8978930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
439 Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol 2019;42:1563-70. [PMID: 31455987 DOI: 10.1007/s00270-019-02317-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
440 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? Front Oncol 2021;11:696183. [PMID: 34178694 DOI: 10.3389/fonc.2021.696183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, Kwon OS, Yeon JE, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial. J Hepatol. 2019;70:684-691. [PMID: 30529387 DOI: 10.1016/j.jhep.2018.11.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 12.8] [Reference Citation Analysis]
442 Liu X, Jiang N, Xu X, Liu C, Liu Z, Zhang Y, Kang W. Anti-Hepatoma Compound Determination by the Method of Spectrum Effect Relationship, Component Knock-Out, and UPLC-MS2 in Scheflera heptaphylla (L.)Frodin Harms and Its Mechanism. Front Pharmacol 2020;11:1342. [PMID: 33013373 DOI: 10.3389/fphar.2020.01342] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG. A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. Metron 2019;77:67-86. [PMID: 31708595 DOI: 10.1007/s40300-019-00151-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
444 Wang E, Xia D, Bai W, Wang Z, Wang Q, Liu L, Wang W, Yuan J, Li X, Chen H, Lv Y, Niu J, He C, Guo W, Yin Z, Luo B, Han N, Wang Z, Yu T, Yuan X, Li K, Tie J, Li C, Cai H, Xia J, Fan D, Han G. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. Invest New Drugs 2019;37:401-14. [PMID: 30019101 DOI: 10.1007/s10637-018-0640-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
445 Qadan M, Fong ZV, Delman AM, Gabr A, Salem R, Shah SA. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma. J Gastrointest Surg 2021. [PMID: 34345997 DOI: 10.1007/s11605-021-05095-x] [Reference Citation Analysis]
446 Sano S, Nakata S, Wada S, Kuroiwa M, Sakai H, Kusama K, Machida T, Nishio A, Ito I, Sodeyama H. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report. World J Surg Oncol 2019;17:229. [PMID: 31878937 DOI: 10.1186/s12957-019-1772-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
447 Foerster F, Galle PR. Hepatocellular carcinoma: one world, one cancer-different guidelines? Hepatobiliary Surg Nutr 2018;7:41-3. [PMID: 29532810 DOI: 10.21037/hbsn.2018.01.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
448 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018; 6(6): 110-120 [PMID: 29988930 DOI: 10.12998/wjcc.v6.i6.110] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
449 Xu Y, Guo Q, Wei L. The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5096. [PMID: 34680245 DOI: 10.3390/cancers13205096] [Reference Citation Analysis]
450 Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
451 Müller L, Hahn F, Jungmann F, Mähringer-Kunz A, Stoehr F, Halfmann MC, Pinto Dos Santos D, Hinrichs J, Auer TA, Düber C, Kloeckner R. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis? Cancer Imaging 2022;22:5. [PMID: 35016731 DOI: 10.1186/s40644-022-00446-6] [Reference Citation Analysis]
452 Li FY, Li JG, Wu SS, Ye HL, He XQ, Zeng QJ, Zheng RQ, An C, Li K. An Optimal Ablative Margin of Small Single Hepatocellular Carcinoma Treated with Image-Guided Percutaneous Thermal Ablation and Local Recurrence Prediction Base on the Ablative Margin: A Multicenter Study. J Hepatocell Carcinoma 2021;8:1375-88. [PMID: 34815974 DOI: 10.2147/JHC.S330746] [Reference Citation Analysis]
453 Choi HH, Perez MG, Millet JD, Liang T, Wasnik AP, Maturen KE, Kamaya A. Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS. Abdom Radiol 2019;44:1415-22. [DOI: 10.1007/s00261-018-1862-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
454 Shi XB, Feng JK, Wang JH, Jiang XQ. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. Ann Transl Med 2021;9:641. [PMID: 33987339 DOI: 10.21037/atm-20-6748] [Reference Citation Analysis]
455 Gupta P, Maralakunte M, Kumar-M P, Chandel K, Chaluvashetty SB, Bhujade H, Kalra N, Sandhu MS. Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC: a systematic review and Bayesian network meta-analysis. Eur Radiol 2021;31:5400-8. [PMID: 33439319 DOI: 10.1007/s00330-020-07610-1] [Reference Citation Analysis]
456 Zhang BH, Li B, Kong LX, Yan LN, Yang JY. Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis. PLoS One 2019;14:e0223514. [PMID: 31600291 DOI: 10.1371/journal.pone.0223514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Yen TH, Chang CH, Shiu SI. Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:367-72. [PMID: 32884512 DOI: 10.1159/000508583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Gazelakis K, Majeed A, Kemp W, Di Muzio B, Gerstenmaier J, Cheung W, Roberts SK. Liver disease severity predicts carcinogenesis of dysplastic liver nodules in cirrhosis. Sci Rep 2021;11:20954. [PMID: 34697374 DOI: 10.1038/s41598-021-00474-5] [Reference Citation Analysis]
459 Robinson A, Ohri A, Liu B, Bhuket T, Wong RJ. One in five hepatocellular carcinoma patients in the United States are Hispanic while less than 40% were eligible for liver transplantation. World J Hepatol 2018; 10(12): 956-965 [PMID: 30631400 DOI: 10.4254/wjh.v10.i12.956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
460 Rich NE, Carr C, Yopp AC, Marrero JA, Singal AG. Racial and Ethnic Disparities in Survival Among Patients With Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31725-0. [PMID: 33387668 DOI: 10.1016/j.cgh.2020.12.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
461 Yang YC, Chien MH, Lai TC, Tung MC, Jan YH, Chang WM, Jung SM, Chen MH, Yeh CN, Hsiao M. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J Biomed Sci 2021;28:29. [PMID: 33888099 DOI: 10.1186/s12929-021-00727-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
462 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
463 Long H, Zhong X, Su L, Huang T, Duan Y, Ke W, Xie X, Lin M. Liver Stiffness Measured by Two-Dimensional Shear Wave Elastography for Predicting Symptomatic Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34379248 DOI: 10.1245/s10434-021-10563-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Liao Y, Wang C, Yang Z, Liu W, Yuan Y, Li K, Zhang Y, Wang Y, Shi Y, Qiu Y, Zuo D, He W, Qiu J, Guan X, Yuan Y, Li B. Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics 2020;10:5209-24. [PMID: 32373208 DOI: 10.7150/thno.43640] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
465 Rimola J, Forner A. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Liver Int 2021;41:888-90. [PMID: 33861894 DOI: 10.1111/liv.14883] [Reference Citation Analysis]
466 Chi C, Chau G, Lee R, Chen Y, Lei H, Hou M, Chao Y, Huang Y. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. Journal of the Formosan Medical Association 2020;119:125-33. [DOI: 10.1016/j.jfma.2019.02.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
467 Aboughaleb IH, Matboli M, Shawky SM, El-Sharkawy YH. Integration of transcriptomes analysis with spectral signature of total RNA for generation of affordable remote sensing of Hepatocellular carcinoma in serum clinical specimens. Heliyon 2021;7:e06388. [PMID: 33748469 DOI: 10.1016/j.heliyon.2021.e06388] [Reference Citation Analysis]
468 Scaglione S, Adams W, Caines A, Devlin P, Mittal S, Singal AG, Parikh ND. Association Between Race/Ethnicity and Insurance Status with Outcomes in Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2020;65:1669-1678. [PMID: 31643036 DOI: 10.1007/s10620-019-05890-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
469 Guerrini GP, Berretta M, Guaraldi G, Magistri P, Esposito G, Ballarin R, Serra V, Di Sandro S, Di Benedetto F. Liver Transplantation for HCC in HIV-Infected Patients: Long-Term Single-Center Experience. Cancers (Basel) 2021;13:4727. [PMID: 34572954 DOI: 10.3390/cancers13184727] [Reference Citation Analysis]
470 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matching. Hepatol Res 2019;50:75-83. [DOI: 10.1111/hepr.13427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
471 Okamura S, Shimose S, Niizeki T, Kamachi N, Noda Y, Shirono T, Iwamoto H, Nakano M, Kuromatsu R, Koga H, Torimura T. Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. Mol Clin Oncol 2022;16:8. [PMID: 34881028 DOI: 10.3892/mco.2021.2442] [Reference Citation Analysis]
472 Zhang PF, Gao C, Huang XY, Lu JC, Guo XJ, Shi GM, Cai JB, Ke AW. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer 2020;19:110. [PMID: 32593303 DOI: 10.1186/s12943-020-01222-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 21.5] [Reference Citation Analysis]
473 Galati G, Massimo Vainieri AF, Maria Fulgenzi CA, Di Donato S, Silletta M, Gallo P, Onorato A, Vespasiani-Gentilucci U, Picardi A. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis. Curr Drug Metab 2020;21:866-84. [PMID: 32957880 DOI: 10.2174/1389200221999200918141239] [Reference Citation Analysis]
474 Guo L, Zheng J, Luo J, Zhang Z, Shao G. Targeting Yes1 Associated Transcriptional Regulator Inhibits Hepatocellular Carcinoma Progression and Improves Sensitivity to Sorafenib: An in vitro and in vivo Study. Onco Targets Ther 2020;13:11071-87. [PMID: 33149619 DOI: 10.2147/OTT.S249412] [Reference Citation Analysis]
475 Martelletti C, Ricotti A, Gesualdo M, Carucci P, Gaia S, Rolle E, Burlone ME, Okolicsanyi S, Mattalia A, Pirisi M, Berchialla P, Tabone M. Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and Bayesian analysis. J Dig Dis 2021;22:496-502. [PMID: 34189839 DOI: 10.1111/1751-2980.13030] [Reference Citation Analysis]
476 Nimitrungtawee N, Inmutto N, Chattipakorn SC, Chattipakorn N. Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34708589 DOI: 10.1002/cam4.4370] [Reference Citation Analysis]
477 Yang J, Zhang YH, Li JW, Shi YY, Huang JY, Luo Y, Liu JB, Lu Q. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Gastroenterol 2020; 26(46): 7325-7337 [PMID: 33362387 DOI: 10.3748/wjg.v26.i46.7325] [Reference Citation Analysis]
478 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Moriyama M. Application of artificial intelligence in hepatology: Minireview. Artif Intell Gastroenterol 2020; 1(1): 5-11 [DOI: 10.35712/aig.v1.i1.5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
479 Li N, Luo L, Wei J, Liu Y, Haque N, Huang H, Qi Y, Huang Z. Identification of a new TRAF6 inhibitor for the treatment of hepatocellular carcinoma. Int J Biol Macromol 2021;182:910-20. [PMID: 33865893 DOI: 10.1016/j.ijbiomac.2021.04.081] [Reference Citation Analysis]
480 Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
481 Zhou J, Ke Y, Lei X, Wu T, Li Y, Bao T, Tang H, Zhang C, Wu X, Wang G, Li J, Zhang H, Ni F, Ye Z, Wang L. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. Ann Hepatol 2020;19:320-8. [PMID: 31980358 DOI: 10.1016/j.aohep.2019.11.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
482 Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma 2020;7:143-53. [PMID: 32984091 DOI: 10.2147/JHC.S258930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
483 Komiyama S, Numata K, Ogushi K, Chuma M, Tanaka R, Chiba S, Otani M, Inayama Y, Nakano M, Maeda S. Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. Diagnostics (Basel) 2021;11:1394. [PMID: 34441328 DOI: 10.3390/diagnostics11081394] [Reference Citation Analysis]
484 Chopra S, George K, Engineer R, Rajamanickam K, Nojin S, Joshi K, Swamidas J, Shetty N, Patkar S, Patil P, Ostwal V, Mehta S, Goel M. Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. Br J Radiol 2019;92:20181053. [PMID: 31219706 DOI: 10.1259/bjr.20181053] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
485 Kim DK, An C, Chung YE, Choi JY, Lim JS, Park MS, Kim MJ. Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free Survival. Radiology 2019;293:594-604. [PMID: 31592730 DOI: 10.1148/radiol.2019190414] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
486 Zhang L, Hu J, Hou J, Jiang X, Guo L, Tian L. Radiomics-based model using gadoxetic acid disodium-enhanced MR images: associations with recurrence-free survival of patients with hepatocellular carcinoma treated by surgical resection. Abdom Radiol (NY) 2021;46:3845-54. [PMID: 33733337 DOI: 10.1007/s00261-021-03034-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
487 Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, Gautam D, Choudhary NS, Thiagarajan S, Rastogi A, Saraf N, Saigal S. Experience With LDLT in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis Postdownstaging. Transplantation 2020;104:2334-45. [PMID: 32032291 DOI: 10.1097/TP.0000000000003162] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
488 Chon HY, Seo YS, Lee JI, Kim BS, Jang BK, Kim SG, Suk KT, Kim IH, Lee JW, Chon YE, Kim MY, Jeong SW, Lee HA, Yim SY, Um SH, Lee HW, Lee KS, Song JE, Lee CH, Chung WJ, Hwang JS, Yoo JJ, Kim YS, Kim DJ, Lee CH, Yu JH, Ha YJ, Kim MN, Lee JH, Hwang SG, Kang SH, Baik SK, Jang JY, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:885-93. [PMID: 32541238 DOI: 10.1097/MEG.0000000000001794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
489 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
490 Kim HY, Nam JY, Lee J, Lee HA, Chang Y, Lee HY, Cho H, Lee DH, Cho YY, Cho EJ, Yu SJ, Lee JM, Kim YJ, Yoon J. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther 2018;47:1490-501. [DOI: 10.1111/apt.14623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
491 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Reference Citation Analysis]
492 Bejjani A, Finn RS. The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:51-5. [PMID: 31508220 DOI: 10.1002/cld.815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
493 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
494 Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, Ngan ES, Lo C, Man K, Ding J, Lee TK, Ma S. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Journal of Hepatology 2018;69:826-39. [DOI: 10.1016/j.jhep.2018.05.034] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 12.5] [Reference Citation Analysis]
495 Sinn DH, Choi GS, Park HC, Kim JM, Kim H, Song KD, Kang TW, Lee MW, Rhim H, Hyun D, Cho SK, Shin SW, Jeong WK, Kim SH, Yu JI, Ha SY, Lee SJ, Lim HY, Kim K, Ahn JH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Joh JW, Lim HK, Paik SW. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019;14:e0210730. [PMID: 30640924 DOI: 10.1371/journal.pone.0210730] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
496 Khatri G, Pedrosa I, Ananthakrishnan L, Leon AD, Fetzer DT, Leyendecker J, Singal AG, Xi Y, Yopp A, Yokoo T. Abbreviated‐protocol screening MRI vs. complete‐protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI‐RADS v2018. J Magn Reson Imaging 2019;51:415-25. [DOI: 10.1002/jmri.26835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
497 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
498 Shi L, Zhang SJ, Chen J, Lu SX, Fan XJ, Tong JH, Chow C, Tin EK, Chan SL, Chong CC, Lai PB, To KF, Wong N, Chan AW. A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Mod Pathol 2019;32:1646-56. [PMID: 31231126 DOI: 10.1038/s41379-019-0307-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
499 Majeed A, Roberts SK, Kemp W. RE: No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology 2019;156:1217. [DOI: 10.1053/j.gastro.2018.09.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
500 Bansal S, Lu F, Frehlich L, Wong JK, Burak KW, Wilson SR. A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS. Abdom Radiol (NY) 2021. [PMID: 34800161 DOI: 10.1007/s00261-021-03331-1] [Reference Citation Analysis]
501 Katrich A, Petrovskiy A, Katrich N, Porkhanov V. Ultrasound in a differentiated treatment approach for liver diseases. Khir Z im N I Pirogova 2021. [DOI: 10.17116/hirurgia202112134] [Reference Citation Analysis]
502 Rutledge B, Jan J, Benjaram S, Sahni N, Naylor P, Philip P, Ehrinpreis M, Mutchnick M. Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center. J Gastrointest Cancer 2020;51:972-9. [PMID: 31792736 DOI: 10.1007/s12029-019-00342-6] [Reference Citation Analysis]
503 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Reference Citation Analysis]
504 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
505 Geist BK, Wang J, Wang X, Lin J, Yang X, Zhang H, Li F, Zhao H, Hacker M, Huo L, Li X. Comparison of different kinetic models for dynamic 18 F-FDG PET/CT imaging of hepatocellular carcinoma with various, also dual-blood input function. Phys Med Biol 2020;65:045001. [DOI: 10.1088/1361-6560/ab66e3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
506 Cruz CR, Carvalho ARMR, Maranhão ACN, Aroucha DB, Foinquinos GA, Carvalho SRC, Vasconcelos LRS, Pereira LMMB. Clinical and laboratory parameters associated with li-rads as diagnostic of liver nodule in patients with cirrhosis. Transl Gastroenterol Hepatol 2021;6:55. [PMID: 34805577 DOI: 10.21037/tgh.2020.01.05] [Reference Citation Analysis]
507 Yuan G, Song Y, Li Q, Hu X, Zang M, Dai W, Cheng X, Huang W, Yu W, Chen M, Guo Y, Zhang Q, Chen J. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients. Front Immunol 2020;11:613946. [PMID: 33488622 DOI: 10.3389/fimmu.2020.613946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
508 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
509 Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020;72:262-276. [PMID: 31954491 DOI: 10.1016/j.jhep.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 26.0] [Reference Citation Analysis]
510 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Kloeckner R. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. Cancers (Basel) 2021;13:3961. [PMID: 34439116 DOI: 10.3390/cancers13163961] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
511 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
512 Shi J, Chen L, Chen Y, Lu Y, Chen X, Yang Z. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. J Cancer 2019;10:4892-901. [PMID: 31598161 DOI: 10.7150/jca.32768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
513 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
514 Manzini G, Hines IN, Henne-Bruns D, Kremer M. Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines. HPB (Oxford) 2020;22:1206-15. [PMID: 31959487 DOI: 10.1016/j.hpb.2019.12.009] [Reference Citation Analysis]
515 Chai Y, Li K, Zhang C, Chen S, Ma K. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer 2019;19:497. [PMID: 31133001 DOI: 10.1186/s12885-019-5707-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
516 Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Reference Citation Analysis]
517 Finn RS. Searching for common ground in a global disease. Hepatobiliary Surg Nutr 2018;7:297-9. [PMID: 30221159 DOI: 10.21037/hbsn.2018.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
518 Abreu P, Gorgen A, Griffiths C, Ivanics T, Sapisochin G. Downstaging and Expanded Criteria Hepatocellular Carcinoma Liver Transplantation. Curr Hepatology Rep 2019;18:400-7. [DOI: 10.1007/s11901-019-00492-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
519 Lim TS, Rhee H, Kim GM, Kim SU, Kim BK, Park JY, Ahn SH, Han K, Choi J, Kim DY. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2019;30:1194-1200.e1. [DOI: 10.1016/j.jvir.2019.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
520 Moawad AW, Fuentes D, Khalaf AM, Blair KJ, Szklaruk J, Qayyum A, Hazle JD, Elsayes KM. Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization. Front Oncol 2020;10:572. [PMID: 32457831 DOI: 10.3389/fonc.2020.00572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
521 Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol 2020;14:619-29. [PMID: 32490691 DOI: 10.1080/17474124.2020.1777856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Min JH, Kim SH, Hwang JA, Hyun SH, Ha SY, Choi SY, Kim SW, Kim HS. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas. Eur Radiol 2021;31:3649-60. [PMID: 33211142 DOI: 10.1007/s00330-020-07378-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
523 Wang J, Yang H, Li Q, Wu X, Di G, Fan J, Wei D, Guo C. Novel nanomicelles based on rebaudioside A: A potential nanoplatform for oral delivery of honokiol with enhanced oral bioavailability and antitumor activity. International Journal of Pharmaceutics 2020;590:119899. [DOI: 10.1016/j.ijpharm.2020.119899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
524 Purcell Y, Sartoris R, Paradis V, Vilgrain V, Ronot M. Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. J Gastroenterol Hepatol 2020;35:305-13. [PMID: 31369166 DOI: 10.1111/jgh.14816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
525 Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:6307. [PMID: 34944927 DOI: 10.3390/cancers13246307] [Reference Citation Analysis]
526 Renzulli M, Clemente A, Brocchi S, Milandri M, Lucidi V, Vukotic R, Cappabianca S, Golfieri R. LI-RADS: a great opportunity not to be missed. Eur J Gastroenterol Hepatol 2019;31:283-8. [PMID: 30234643 DOI: 10.1097/MEG.0000000000001269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
527 Mamdouh F, Abdel Alem S, Abdo M, Abdelaal A, Salem A, Rabiee A, Elsisi O. Serum Serotonin as a Potential Diagnostic Marker for Hepatocellular Carcinoma. J Interferon Cytokine Res 2019;39:780-5. [PMID: 31478787 DOI: 10.1089/jir.2019.0088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
528 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 48.0] [Reference Citation Analysis]
529 Yin S, Qiu Y, Jin C, Wang R, Wu S, Liu H, Koo S, Han L, Zhang Y, Gao X, Pang X, Wang T, Yu H. 7‐Deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma. Int J Cancer 2019;145:3334-46. [DOI: 10.1002/ijc.32395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
530 Nakamura Y, Higaki T, Honda Y, Tatsugami F, Tani C, Fukumoto W, Narita K, Kondo S, Akagi M, Awai K. Advanced CT techniques for assessing hepatocellular carcinoma. Radiol Med 2021;126:925-35. [PMID: 33954894 DOI: 10.1007/s11547-021-01366-4] [Reference Citation Analysis]
531 Shousha HI, Abdelaziz AO, Nabeel MM, Omran DA, Abdelmaksoud AH, Elbaz TM, Salah A, Harb STE, Hosny KA, Osman A, Atef M, Gaber A, Zayed NA, Yosry AA, Leithy R. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade. Pathog Glob Health 2021;:1-9. [PMID: 34494507 DOI: 10.1080/20477724.2021.1975081] [Reference Citation Analysis]
532 Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. DEB-TACE: a standard review. Future Oncol. 2018;14:2969-2984. [PMID: 29987957 DOI: 10.2217/fon-2018-0136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
533 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
534 Huang TH, Lin MT, Wang JH, Chang KC, Yen YH, Kuo FY, Huang CC, Hsiao CC, Chiu SY, Lu SN, Wang CC, Hu TH. Clinical and novel application of FibroScan, FIB-4 and aspartate aminotransferase-to-platelet ratio index in liver fibrosis evaluation in patients with hepatocellular carcinoma and their roles in oesophageal variceal prediction. Int J Clin Pract 2021;75:e13945. [PMID: 33338308 DOI: 10.1111/ijcp.13945] [Reference Citation Analysis]
535 Cools KS, Moon AM, Burke LMB, McGinty KA, Strassle PD, Gerber DA. Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transpl 2020;26:203-14. [PMID: 31677319 DOI: 10.1002/lt.25673] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
536 Yoo S, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Ryoo BY, Choi J. Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00683-2. [PMID: 34182151 DOI: 10.1016/j.cgh.2021.06.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
537 West CA, Black AP, Mehta AS. Analysis of Hepatocellular Carcinoma Tissue for Biomarker Discovery. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 93-107. [DOI: 10.1007/978-3-030-21540-8_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Fan CT, Lin WW, Chen MJ, Shiu SI. Isolated Right Ventricular Metastasis in a Woman with Advanced Hepatocellular Carcinoma after Palliative Therapy. Case Rep Gastroenterol 2019;13:487-97. [PMID: 31911761 DOI: 10.1159/000504566] [Reference Citation Analysis]
539 Guss D, Sherigar J, Mohanty SR. Missed Diagnosis of Liver Cirrhosis Leads to Disparities in Care for Older Patients. Gastroenterology Res 2018;11:333-9. [PMID: 30344803 DOI: 10.14740/gr1074w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
540 Wang E, Xia D, Bai W, Yuan J, Li X, Niu J, Yin Z, Xia J, Cai H, Fan D, Han G, Liu L. Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma. BMC Cancer 2019;19:409. [PMID: 31039750 DOI: 10.1186/s12885-019-5570-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
541 Rimola J, Da Fonseca LG, Sapena V, Perelló C, Guerrero A, Simó MT, Pons M, De La Torre-Aláez M, Márquez L, Calleja JL, Lledó JL, Varela M, Mínguez B, Sangro B, Matilla A, Torres F, Ayuso C, Bruix J, Reig M. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. Eur J Radiol 2021;135:109484. [PMID: 33383399 DOI: 10.1016/j.ejrad.2020.109484] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
542 Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2021;12:e00310. [PMID: 33605612 DOI: 10.14309/ctg.0000000000000310] [Reference Citation Analysis]
543 Qiu C, Li Z, Cao W, Cai X, Ye L, Zhang C, Ma Y, Wang X, Yang Y. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma. Biosci Rep 2021;41:BSR20203978. [PMID: 34435618 DOI: 10.1042/BSR20203978] [Reference Citation Analysis]
544 Noreikaite J, Albasha D, Chidambaram V, Arora A, Katti A. Indeterminate liver lesions on gadoxetic acid-enhanced magnetic resonance imaging of the liver: Case-based radiologic-pathologic review. World J Hepatol 2021; 13(9): 1079-1097 [PMID: 34630876 DOI: 10.4254/wjh.v13.i9.1079] [Reference Citation Analysis]
545 Sun YF, Wang PX, Cheng JW, Gong ZJ, Huang A, Zhou KQ, Hu B, Gao PT, Cao Y, Qiu SJ, Zhou J, Fan J, Guo W, Yang XR. Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol 2020;128:733-45. [PMID: 32501632 DOI: 10.1002/cncy.22304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
546 Hesh CA, Gill AE, Soler Rodriguez D, Clifton MS, Mitchell S, Hawkins CM. Percutaneous image-guided microwave ablation as primary therapy for PRETEXT II hepatoblastoma. Pediatr Blood Cancer 2020;67:e28641. [PMID: 32776446 DOI: 10.1002/pbc.28641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
547 Fronda M, Doriguzzi Breatta A, Gatti M, Calandri M, Maglia C, Bergamasco L, Righi D, Faletti R, Fonio P. Quantitative assessment of HCC wash-out on CT is a predictor of early complete response to TACE. Eur Radiol 2021;31:6578-88. [PMID: 33738601 DOI: 10.1007/s00330-021-07792-2] [Reference Citation Analysis]
548 Song M, Park HJ, Lee ES, Ahn HS, Park SB. Value of precontrast and portal venous phases for evaluating atypical hepatocellular carcinoma mimicking arterioportal shunt. Eur J Radiol 2021;143:109933. [PMID: 34492626 DOI: 10.1016/j.ejrad.2021.109933] [Reference Citation Analysis]
549 Mai R, Zeng J, Lu H, Liang R, Lin Y, Piao X, Gao X, Wu G, Wu F, Ma L, Xiang B, Li L, Ye J. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:688-97. [DOI: 10.1007/s11605-020-04575-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
550 Chu MO, Shen CH, Chang TS, Xu HW, Yen CW, Lu SN, Hung CH. Pretreatment Inflammation-Based Markers Predict Survival Outcomes in Patients with Early Stage Hepatocellular Carcinoma After Radiofrequency Ablation. Sci Rep 2018;8:16611. [PMID: 30413724 DOI: 10.1038/s41598-018-34543-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
551 Sanchez JI, Jiao J, Kwan SY, Veillon L, Warmoes MO, Tan L, Odewole M, Rich NE, Wei P, Lorenzi PL, Singal AG, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila) 2021;14:955-62. [PMID: 34253566 DOI: 10.1158/1940-6207.CAPR-20-0612] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
552 Wang X, Liang H, Lu Z. Efficacy of transarterial chemoembolization compared with radiofrequency ablation for the treatment of recurrent hepatocellular carcinoma after radiofrequency ablation. Minim Invasive Ther Allied Technol 2020;29:344-52. [PMID: 31375044 DOI: 10.1080/13645706.2019.1649286] [Reference Citation Analysis]
553 Duan Y, Xie X, Li Q, Mercaldo N, Samir AE, Kuang M, Lin M. Differentiation of regenerative nodule, dysplastic nodule, and small hepatocellular carcinoma in cirrhotic patients: a contrast-enhanced ultrasound-based multivariable model analysis. Eur Radiol 2020;30:4741-51. [PMID: 32307563 DOI: 10.1007/s00330-020-06834-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
554 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
555 Gupta P, Kalra N, Keshava SN, Chaluvashetty SB, Mukund A, Roy-choudhury SH, Baijal SS, Khandelwal A, Ananthashayana VH, R. SN, Kulkarni S, Shetty NS, Gupta A, Gupta S. Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part I. Journal of Clinical Interventional Radiology ISVIR 2020;4:098-106. [DOI: 10.1055/s-0040-1715774] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
556 Ding GY, Zhu XD, Ji Y, Shi GM, Shen YH, Zhou J, Fan J, Sun HC, Huang C. Serum PON1 as a biomarker for the estimation of microvascular invasion in hepatocellular carcinoma. Ann Transl Med 2020;8:204. [PMID: 32309351 DOI: 10.21037/atm.2020.01.44] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
557 Carrion AF, Martin P. When to Refer for Liver Transplantation. Am J Gastroenterol 2019;114:7-10. [PMID: 30171217 DOI: 10.1038/s41395-018-0242-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
558 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
559 Cheng JT, Tan NE, Volk ML. Utility of positron emission tomography-computed tomography scan in detecting residual hepatocellular carcinoma post treatment: Series of case reports. World J Gastrointest Oncol 2020; 12(3): 358-364 [PMID: 32206185 DOI: 10.4251/wjgo.v12.i3.358] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
560 Liu X, Gao H, Zhang J, Xue D. FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma. Biosci Rep 2019;39:BSR20181640. [PMID: 30910840 DOI: 10.1042/BSR20181640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
561 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019;25:369-79. [PMID: 30582779 DOI: 10.1002/lt.25398] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
562 Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int 2021. [PMID: 34687130 DOI: 10.1111/liv.15085] [Reference Citation Analysis]
563 Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, Maeda S, Tanaka K, Numata K. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. Hepatology. 2019;69:2533-2545. [PMID: 30805950 DOI: 10.1002/hep.30591] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
564 Yan L, Zhang Y, Jiang B, Luo Y. Radiofrequency Ablation for Cervical Metastatic Lymph Nodes in Children and Adolescents With Papillary Thyroid Carcinoma: A Preliminary Study. Front Endocrinol (Lausanne) 2021;12:624054. [PMID: 34084150 DOI: 10.3389/fendo.2021.624054] [Reference Citation Analysis]
565 Yim SY, Lee J. The Genomic Landscape and Its Clinical Implications in Hepatocellular Carcinoma. J Liver Cancer 2019;19:97-107. [DOI: 10.17998/jlc.19.2.97] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
566 Musa NI, Mohamed IE, Abohalima AS. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00035-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
567 Uchino K, Tateishi R, Wake T, Kinoshita MN, Nakagomi R, Nakatsuka T, Minami T, Sato M, Enooku K, Nakagawa H, Shiina S, Koike K. Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. J Vasc Interv Radiol 2021;32:869-77. [PMID: 33689831 DOI: 10.1016/j.jvir.2021.02.021] [Reference Citation Analysis]
568 Foerster F, Galle PR. Ultrasound for Hepatocellular Carcinoma Surveillance: Still Looking for the Fortune Teller. Liver Transpl 2018;24:1167-8. [PMID: 30021053 DOI: 10.1002/lt.25309] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
569 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
570 Chen Y, Wang X, Deng X, Zhang Y, Liao R, Li Y, Yang H, Chen K. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Front Immunol 2021;12:676922. [PMID: 34335575 DOI: 10.3389/fimmu.2021.676922] [Reference Citation Analysis]
571 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
572 Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic Treatment for Advanced Hepatocellular Carcinoma. Liver Cancer. 2019;8:341-358. [PMID: 31768344 DOI: 10.1159/000496439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
573 Falcon T, Freitas M, Mello AC, Coutinho L, Alvares-da-Silva MR, Matte U. Analysis of the Cancer Genome Atlas Data Reveals Novel Putative ncRNAs Targets in Hepatocellular Carcinoma. Biomed Res Int 2018;2018:2864120. [PMID: 30046591 DOI: 10.1155/2018/2864120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
574 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
575 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
576 Song BG, Kim MJ, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Dig Liver Dis 2021;53:210-5. [PMID: 33189588 DOI: 10.1016/j.dld.2020.10.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
577 Kim YY, An C, Kim DY, Aljoqiman KS, Choi JY, Kim MJ. Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography 2019;38:311-20. [PMID: 31079440 DOI: 10.14366/usg.18051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
578 Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AX. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer 2017;6:360-74. [PMID: 29234639 DOI: 10.1159/000481315] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
579 Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
580 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma ≤5 cm: A propensity score-matched analysis. Surgery 2019;166:254-62. [PMID: 31279438 DOI: 10.1016/j.surg.2019.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
581 Kang HJ, Kim H, Lee DH, Hur BY, Hwang YJ, Suh KS, Han JK. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery. Radiology 2021;:204352. [PMID: 34227881 DOI: 10.1148/radiol.2021204352] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
582 Abdel Razek AAK, El-Serougy LG, Saleh GA, Shabana W, Abd El-Wahab R. Liver Imaging Reporting and Data System Version 2018: What Radiologists Need to Know. J Comput Assist Tomogr. 2020;44:168-177. [PMID: 32195795 DOI: 10.1097/rct.0000000000000995] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 11.5] [Reference Citation Analysis]
583 Li Z, Hu Y, Wang H, Wang M, Gu X, Ping Y, Zeng Q, Li H, Yan J, Yu Z. Predictors for the progression of hepatic cirrhosis to hepatocellular carcinoma under long-term antiviral therapy. Eur J Gastroenterol Hepatol 2020;32:447-53. [PMID: 32012142 DOI: 10.1097/MEG.0000000000001631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
584 Wang M, Fu F, Zheng B, Bai Y, Wu Q, Wu J, Sun L, Liu Q, Liu M, Yang Y, Shen H, Kong D, Ma X, You P, Li X, Tian F. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data. Br J Cancer 2021. [PMID: 34365472 DOI: 10.1038/s41416-021-01511-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Ocker M. Biomarkers for hepatocellular carcinoma: What’s new on the horizon? World J Gastroenterol 2018; 24(35): 3974-3979 [PMID: 30254402 DOI: 10.3748/wjg.v24.i35.3974] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
586 Fathi F, Sanei B, Ganjalikhani Hakemi M, Saidi RF, Rezaei A. Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:5593655. [PMID: 33987145 DOI: 10.1155/2021/5593655] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 El-Nakeep S. Molecular and genetic markers in hepatocellular carcinoma: In silico analysis to clinical validation (current limitations and future promises). World J Gastrointest Pathophysiol 2022; 13(1): 1-14 [DOI: 10.4291/wjgp.v13.i1.1] [Reference Citation Analysis]
588 Beumer BR, de Wilde RF, Metselaar HJ, de Man RA, Polak WG, Ijzermans JNM. The Treatment Effect of Liver Transplantation versus Liver Resection for HCC: A Review and Future Perspectives. Cancers (Basel) 2021;13:3730. [PMID: 34359629 DOI: 10.3390/cancers13153730] [Reference Citation Analysis]
589 Souhami A, Sartoris R, Rautou PE, Cauchy F, Bouattour M, Durand F, Giannelli V, Gigante E, Castera L, Valla D, Soubrane O, Vilgrain V, Ronot M. Similar performance of liver stiffness measurement and liver surface nodularity for the detection of portal hypertension in patients with hepatocellular carcinoma. JHEP Rep 2020;2:100147. [PMID: 32885156 DOI: 10.1016/j.jhepr.2020.100147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
590 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
591 Huber TC, Bochnakova T, Koethe Y, Park B, Farsad K. Percutaneous Therapies for Hepatocellular Carcinoma: Evolution of Liver Directed Therapies. J Hepatocell Carcinoma 2021;8:1181-93. [PMID: 34589446 DOI: 10.2147/JHC.S268300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
593 Youn SY, Kim DH, Choi JI, Choi MH, Kim B, Shin YR, Oh SN, Rha SE. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI. Korean J Radiol 2021;22:1289-99. [PMID: 34047507 DOI: 10.3348/kjr.2020.1394] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
594 Vorobioff JD, Contreras F, Tanno F, Hernández L, Bessone F, Colombato L, Adi J, Fassio E, Felgueres M, Fernández G, Gaite L, Gibelli D, Darrichon HG, Lafage M, Lombardo D, López S, Mateo A, Mendizábal M, Pecoraro J, Ruf A, Ruiz P, Severini J, Stieben T, Sixto M, Zárate F, Barraza SB, Sierra ID, Pacheco VR, Roblero JP, Rojas JO, González PR, Rodríguez DSM, Sierralta A, Manchego AU, Valdes E, Yaquich P, Wolff R, Valdivia FB, Gallegos RC, Galloso R, Marcelo JS, Montes P, Tenorio L, Veramendi I, Alava E, Armijos X, Benalcazar G, Carrera E, Pazmiño GF, Díaz EM, Garassini M, Marrero RP, Infante M, Suárez DP, Gutiérrez JC, Reyes CMV, Serrano YM, Hernández RH, Martínez OM, González TP, Andara MT, Hernández MS, Gerona S, García I, Tijera F, López EP, Torres K, Garzón M. A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Ann Hepatol 2020;19:396-403. [PMID: 32418749 DOI: 10.1016/j.aohep.2020.03.007] [Reference Citation Analysis]
595 Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother. 2019;68:23-32. [PMID: 30232520 DOI: 10.1007/s00262-018-2247-4] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
596 M Cunha G, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, Marks RM, Cruite I, Horvat N, Chernyak V, Sirlin CB, Tang A. How to Use LI-RADS to Report Liver CT and MRI Observations. Radiographics 2021;41:1352-67. [PMID: 34297631 DOI: 10.1148/rg.2021200205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Bayle M, Clerc-Urmès I, Ayav A, Bronowicki JP, Petit I, Orry X, Laurent V. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. Abdom Radiol (NY) 2019;44:85-94. [PMID: 30054686 DOI: 10.1007/s00261-018-1714-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
598 Shen ZF, Liang X. Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension. World J Clin Cases 2021; 9(11): 2419-2432 [PMID: 33889608 DOI: 10.12998/wjcc.v9.i11.2419] [Reference Citation Analysis]
599 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
600 Cho WR, Hung CH, Chen CH, Lin CC, Wang CC, Liu YW, Wu YJ, Yong CC, Chen KD, Tsai YC, Hu TH, Tsai MC. Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery. Sci Rep 2020;10:7290. [PMID: 32350365 DOI: 10.1038/s41598-020-64354-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
601 Bannaga A, Arasaradnam RP. Neutrophil to lymphocyte ratio and albumin bilirubin grade in hepatocellular carcinoma: A systematic review. World J Gastroenterol 2020; 26(33): 5022-5049 [PMID: 32952347 DOI: 10.3748/wjg.v26.i33.5022] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
602 Zhang XY, Ou J, Chen JY, Li WW. Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward. J Hepatol 2019;70:567-8. [PMID: 30554930 DOI: 10.1016/j.jhep.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
603 Bannaga AS, Tyagi H, Daulton E, Covington JA, Arasaradnam RP. Exploratory Study Using Urinary Volatile Organic Compounds for the Detection of Hepatocellular Carcinoma. Molecules 2021;26:2447. [PMID: 33922256 DOI: 10.3390/molecules26092447] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
604 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
605 Ruohoniemi DM, Taslakian B, Aaltonen EA, Hickey R, Patel A, Horn JC, Chiarello M, Mcdermott M. Comparative Analysis of Safety and Efficacy of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma in Patients with and without Pre-Existing Transjugular Intrahepatic Portosystemic Shunts. Journal of Vascular and Interventional Radiology 2020;31:409-15. [DOI: 10.1016/j.jvir.2019.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
606 Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 3980-3999 [PMID: 30254403 DOI: 10.3748/wjg.v24.i35.3980] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
607 Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol 2020;30:5650-62. [PMID: 32409860 DOI: 10.1007/s00330-020-06911-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Kang B, Choi WS, Kang JH, Kim HC, Chung JW, Choi JW. Spectral CT Imaging-Based Quantification of Iodized Oil Retention following Chemoembolization: Phantom and Animal Studies. J Vasc Interv Radiol 2020;31:503-509.e1. [PMID: 32007404 DOI: 10.1016/j.jvir.2019.09.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
609 Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, Masch WR, Marks RM, Kamaya A, Do RKG, Kono Y, Fowler KJ, Tang A, Bashir MR, Hecht EM, Jambhekar K, Lyshchik A, Rodgers SK, Heiken JP, Kohli M, Fetzer DT, Wilson SR, Kassam Z, Mendiratta-Lala M, Singal AG, Lim CS, Cruite I, Lee J, Ash R, Mitchell DG, McInnes MDF, Sirlin CB. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.J Hepatocell Carcinoma. 2019;6:49-69. [PMID: 30788336 DOI: 10.2147/JHC.S186239] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
610 Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol 2021:S0748-7983(21)00407-8. [PMID: 33902956 DOI: 10.1016/j.ejso.2021.04.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
611 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
612 Maan R, van der Meer AJ. Hepatocellular carcinoma (HCC) risk stratification after virological cure for hepatitis C virus (HCV)-induced cirrhosis: time to refine predictive models. Hepatobiliary Surg Nutr 2021;10:385-7. [PMID: 34159170 DOI: 10.21037/hbsn-21-95] [Reference Citation Analysis]
613 Muhammad H, Tehreem A, Ting PS, Gurakar M, Li SY, Simsek C, Alqahtani SA, Kim AK, Kohli R, Gurakar A. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review. J Clin Transl Hepatol 2021;9:738-48. [PMID: 34722189 DOI: 10.14218/JCTH.2021.00125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
615 Wang L, Ke Q, Lin N, Huang Q, Zeng Y, Liu J. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2019;36:1288-96. [PMID: 31852267 DOI: 10.1080/02656736.2019.1692148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
616 Wen L, Weng S, Yan C, Ye R, Zhu Y, Zhou L, Gao L, Li Y. A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation. Front Oncol 2021;11:657039. [PMID: 34026632 DOI: 10.3389/fonc.2021.657039] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
617 Tayob N, Christie I, Richardson P, Feng Z, White DL, Davila J, Corley DA, Kanwal F, El-Serag HB. Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:1886-1893.e5. [PMID: 30557738 DOI: 10.1016/j.cgh.2018.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
618 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
619 Zhang L, Liu SY, Yang X, Wang YQ, Cheng YX. TMEM206 is a potential prognostic marker of hepatocellular carcinoma. Oncol Lett 2020;20:174. [PMID: 32934741 DOI: 10.3892/ol.2020.12035] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
620 Wang L, Ke Q, Huang Q, Shao L, Chen J, Wu J. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. International Journal of Hyperthermia 2020;37:1313-21. [DOI: 10.1080/02656736.2020.1843719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
621 Luo X, Sui J, Yang W, Sun Q, Ma Y, Simon TG, Liang G, Meyerhardt JA, Chan AT, Giovannucci EL, Zhang X. Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. Am J Gastroenterol 2019;114:1870-7. [PMID: 31688024 DOI: 10.14309/ajg.0000000000000450] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
622 Facciorusso A, Abd El Aziz MA, Singh S, Pusceddu S, Milione M, Giacomelli L, Sacco R. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis. Cancers (Basel) 2020;12:E874. [PMID: 32260179 DOI: 10.3390/cancers12040874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
623 Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol. 2019;16:411-428. [PMID: 31028350 DOI: 10.1038/s41575-019-0145-7] [Cited by in Crossref: 268] [Cited by in F6Publishing: 286] [Article Influence: 89.3] [Reference Citation Analysis]
624 Thanapirom K, Caon E, Papatheodoridi M, Frenguelli L, Al-Akkad W, Zhenzhen Z, Vilia MG, Pinzani M, Mazza G, Rombouts K. Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer. Cancers (Basel) 2021;13:4936. [PMID: 34638417 DOI: 10.3390/cancers13194936] [Reference Citation Analysis]
625 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 16.7] [Reference Citation Analysis]
626 Pan YX, Fu YZ, Hu DD, Long Q, Wang JC, Xi M, Liu SL, Xu L, Liu MZ, Chen MS, Zhang YJ. Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2020;10:1639. [PMID: 33194569 DOI: 10.3389/fonc.2020.01639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
627 Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver? Ultrasound Med Biol 2021;47:2930-5. [PMID: 34266681 DOI: 10.1016/j.ultrasmedbio.2021.05.004] [Reference Citation Analysis]
628 Kang N, Chung JW, Jang ES, Jeong SH, Kim JW. Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Dig Dis Sci 2021. [PMID: 33630218 DOI: 10.1007/s10620-020-06762-w] [Reference Citation Analysis]
629 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
630 Guo B, Tan X, Cen H. EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PLoS One 2020;15:e0242191. [PMID: 33180829 DOI: 10.1371/journal.pone.0242191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
631 Yun BY, Lee HW, Min IK, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Prognosis of Early-Stage Hepatocellular Carcinoma: Comparison between Trans-Arterial Chemoembolization and Radiofrequency Ablation. Cancers (Basel). 2020;12. [PMID: 32899584 DOI: 10.3390/cancers12092527] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
632 Zhang Y, Zhang J, Chen X, Yang Z. Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma. Int J Med Sci 2021;18:364-71. [PMID: 33390805 DOI: 10.7150/ijms.49790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
633 Bhutiani N, O'brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, Mcmasters KM, Martin RC, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). HPB 2020;22:1330-8. [DOI: 10.1016/j.hpb.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
634 Balitzer D, Kakar S. Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective. Clin Liver Dis (Hoboken) 2021;17:249-54. [PMID: 33968384 DOI: 10.1002/cld.1091] [Reference Citation Analysis]
635 Lucey MR. Alcohol-Associated Cirrhosis. Clin Liver Dis 2019;23:115-26. [PMID: 30454826 DOI: 10.1016/j.cld.2018.09.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
636 Chagas AL, Mattos AA, Diniz MA, Felga GEG, Boin IFSF, Silva RCMA, Silva RF, Garcia JHP, Lima AS, Coelho JCU, Bittencourt PL, Alves VAF, D'Albuquerque LAC, Carrilho FJ; Brazilian HCC Study Group. Impact of Brazilian expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a multicenter study. Ann Hepatol 2021;22:100294. [PMID: 33276136 DOI: 10.1016/j.aohep.2020.100294] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
637 Chon HY, Lee HA, Suh SJ, Lee JI, Kim BS, Kim IH, Lee CH, Jang BK, Lee HW, Hwang JS, Lee CH, Lee JW, Yu JH, Seo YS, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Addition of liver stiffness enhances the predictive accuracy of the PAGE-B model for hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2021;53:919-27. [PMID: 33465253 DOI: 10.1111/apt.16267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
638 Chen K, Wei W, Liu L, Deng ZJ, Li L, Liang XM, Guo PP, Qi LN, Zhang ZM, Gong WF, Huang S, Yuan WP, Ma L, Xiang BD, Li LQ, Zhong JH. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice. Cancer Immunol Immunother 2021. [PMID: 34559308 DOI: 10.1007/s00262-021-03060-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
639 Akutsu Y, Kawamura M, Tanisawa H, Nomura K, Gokan T, Sekimoto T, Kaneko K, Kodama Y, Ohgiya Y, Matsuyama T, Gokan T, Shinke T. Intracardiac Thrombosis and Heart Failure in a Patient with Hepatocellular Carcinoma and Cardiac Amyloidosis and an Implanted Cardiac Resynchronization Therapy Device. Am J Case Rep 2019;20:933-6. [PMID: 31256189 DOI: 10.12659/AJCR.916672] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
640 Kanouchi K, Narimatsu H, Shirata T, Morikane K. Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis. Health Sci Rep 2021;4:e258. [PMID: 33738342 DOI: 10.1002/hsr2.258] [Reference Citation Analysis]
641 Hsiao CY, Hu RH, Ho CM, Wu YM, Lee PH, Ho MC. Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study. Am J Surg 2020;220:958-64. [PMID: 32247523 DOI: 10.1016/j.amjsurg.2020.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
642 Son TQ, Hoc TH, Long VD, Thang NT, Huong TT, Van Tuyen P. Pancreaticoduodenectomy for hepatic portal lymph node metastasis after hepatic resection for hepatocellular carcinoma: A clinical case report. Int J Surg Case Rep 2021;82:105921. [PMID: 33964712 DOI: 10.1016/j.ijscr.2021.105921] [Reference Citation Analysis]
643 Ercolani G, Cucchi M. Surgery for hepatocellular carcinoma can provide the same life-expectancy as transplant of that of general population. Hepatobiliary Surg Nutr 2019;8:151-2. [PMID: 31098365 DOI: 10.21037/hbsn.2018.11.17] [Reference Citation Analysis]
644 Zheng R, Wang L, Wang C, Yu X, Chen W, Li Y, Li W, Yan F, Wang H, Li R. Feasibility of automatic detection of small hepatocellular carcinoma (≤2 cm) in cirrhotic liver based on pattern matching and deep learning. Phys Med Biol 2021;66. [PMID: 33780910 DOI: 10.1088/1361-6560/abf2f8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
645 Bhatti ABH, Hassan M, Rana A, Khan NY, Khan ZA, Zia HH. Risk Score Model for Liver Transplant Outcomes after Preoperative Locoregional Therapy for Hepatocellular Carcinoma. J Gastrointest Cancer 2020. [PMID: 33184772 DOI: 10.1007/s12029-020-00554-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
646 Mahmud N, Kaplan DE, Goldberg DS, Taddei TH, Serper M. Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic. Gastroenterology 2021;160:2162-2164.e3. [PMID: 33434604 DOI: 10.1053/j.gastro.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
647 Narsinh KH, Duncan DP, Newton IG, Minocha J, Rose SC. Liver-directed therapy for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:203-217. [PMID: 29230556 DOI: 10.1007/s00261-017-1435-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
648 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
649 Lin Z, Li S, Guo P, Wang L, Zheng L, Yan Z, Chen X, Cheng Z, Yan H, Zheng C, Zhao C. Columbamine suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK1/2 MAPK signaling pathways. Life Sci 2019;218:197-204. [PMID: 30582951 DOI: 10.1016/j.lfs.2018.12.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
650 Ji M, Liu Z, Chang ET, Yu X, Wu B, Deng L, Feng Q, Wei K, Liang X, Lian S, Quan W, Wang P, Du Y, Liang Z, Xia S, Lin H, Li F, Cheng W, Chen W, Yuan Y, Ye W. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Sci Rep 2018;8:12787. [PMID: 30143694 DOI: 10.1038/s41598-018-31119-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
651 Tang A, Singal AG, Mitchell DG, Hecht EM, Fowler KJ, Kulik L, Parikh ND, Kono Y, Sirlin CB. Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2019;17:1228-38. [DOI: 10.1016/j.cgh.2018.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
652 Kim K, Kim TH, Kim TH, Seong J. Efficacy of Local Therapy for Oligometastatic Hepatocellular Carcinoma: A Propensity Score Matched Analysis. J Hepatocell Carcinoma 2021;8:35-44. [PMID: 33604314 DOI: 10.2147/JHC.S290197] [Reference Citation Analysis]
653 Ji W, Xing Y, Ma J, Zhao Z, Xu H, Zheng S, Li W, Li X. Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review. J Hepatocell Carcinoma 2021;8:1117-27. [PMID: 34522692 DOI: 10.2147/JHC.S325182] [Reference Citation Analysis]
654 Mo D, Jia R, Zhong J. Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward. Hepatology 2019;70:446-7. [DOI: 10.1002/hep.30409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
655 Doyle A, Gorgen A, Muaddi H, Aravinthan AD, Issachar A, Mironov O, Zhang W, Kachura J, Beecroft R, Cleary SP, Ghanekar A, Greig PD, McGilvray ID, Selzner M, Cattral MS, Grant DR, Lilly LB, Selzner N, Renner EL, Sherman M, Sapisochin G. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol 2019;70:866-73. [PMID: 30615906 DOI: 10.1016/j.jhep.2018.12.027] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
656 Jang TY, Wei YJ, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. J Gastroenterol Hepatol 2020;35:1886-92. [PMID: 32247291 DOI: 10.1111/jgh.15061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
657 Bengtsson B, Stål P, Wahlin S, Björkström NK, Hagström H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. Liver Int 2019;39:1098-108. [PMID: 30829446 DOI: 10.1111/liv.14087] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
658 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
659 Fraquelli M, Nadarevic T, Giljaca V, Colli A, Miletic D, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013483] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
660 Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
661 Brar G, Kesselman A, Malhotra A, Shah MA. Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies. JCO Oncol Pract 2021;:OP2100227. [PMID: 34255552 DOI: 10.1200/OP.21.00227] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Ikenaga H, Uchida-Kobayashi S, Tamori A, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kozuka R, Kawamura E, Hagihara A, Fujii H, Enomoto M, Kawada N. Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment. J Viral Hepat 2021. [PMID: 34695288 DOI: 10.1111/jvh.13627] [Reference Citation Analysis]
663 Moriya K, Namisaki T, Takaya H, Kaji K, Kawaratani H, Shimozato N, Sawada Y, Douhara A, Sato S, Furukawa M, Kitagawa K, Akahane T, Yoshiji H. Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy. J Clin Med 2021;10:629. [PMID: 33562238 DOI: 10.3390/jcm10040629] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ikeda N, Aizawa N, Nishimura T, Iijima H, Nishiguchi S. Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2020;10:E238. [PMID: 32325995 DOI: 10.3390/diagnostics10040238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
665 Zhao F, Feng G, Zhu J, Su Z, Guo R, Liu J, Zhang H, Zhai Y. 3-Methyladenine-enhanced susceptibility to sorafenib in hepatocellular carcinoma cells by inhibiting autophagy. Anticancer Drugs 2021;32:386-93. [PMID: 33395067 DOI: 10.1097/CAD.0000000000001032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
666 Gerena M, Molvar C, Masciocchi M, Nandwana S, Sabottke C, Spieler B, Sharma R, Tsai L, Kielar A. LI-RADS treatment response assessment of combination locoregional therapy for HCC. Abdom Radiol (NY) 2021;46:3634-47. [PMID: 34120207 DOI: 10.1007/s00261-021-03165-x] [Reference Citation Analysis]
667 Piñero F, Boin I, Chagas A, Quiñonez E, Marciano S, Vilatobá M, Santos L, Anders M, Hoyos Duque S, Soares Lima A, Menendez J, Padilla M, Poniachik J, Zapata R, Maraschio M, Chong Menéndez R, Muñoz L, Arufe D, Figueroa R, Mendizabal M, Hurtado Gomez S, Stucchi R, Maccali C, Vergara Sandoval R, Bermudez C, McCormack L, Varón A, Gadano A, Mattera J, Rubinstein F, Carrilho F, Silva M. Direct-Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Wait-List Progression or Posttransplant Recurrence. Liver Transpl 2020;26:640-50. [PMID: 32133773 DOI: 10.1002/lt.25744] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
668 Goedeke L, Shulman GI. Therapeutic potential of mitochondrial uncouplers for the treatment of metabolic associated fatty liver disease and NASH. Mol Metab 2021;46:101178. [PMID: 33545391 DOI: 10.1016/j.molmet.2021.101178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
669 Pham AD, Vaz K, Ardalan ZS, Sinclair M, Apostolov R, Gardner S, Majeed A, Mishra G, Kam NM, Patwala K, Kutaiba N, Arachchi N, Bell S, Dev AT, Lubel JS, Nicoll AJ, Sood S, Kemp W, Roberts SK, Fink M, Testro AG, Angus PW, Gow PJ. Clinical outcomes of patients with two small hepatocellular carcinomas. World J Hepatol 2021; 13(10): 1439-1449 [PMID: 34786178 DOI: 10.4254/wjh.v13.i10.1439] [Reference Citation Analysis]
670 Park SH, Shim YS, Kim B, Kim SY, Kim YS, Huh J, Park JH, Kim KW, Lee SS. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. Eur Radiol 2021;31:4751-63. [PMID: 33389037 DOI: 10.1007/s00330-020-07577-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
671 Zhou Y, Ouyang J, Wang Z, Chen X, Zhu R, Li Q, Zhou J. A novel internal cold circulation radiofrequency-assisted device for liver transection. Int J Hyperthermia 2021;38:308-15. [PMID: 33627010 DOI: 10.1080/02656736.2021.1889046] [Reference Citation Analysis]
672 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Superselective Transarterial Chemoembolization for Unresectable or "Ablation Unsuitable" Hepatocellular Carcinoma in the Caudate Lobe: A Real World, Single-Center Retrospective Study. Front Oncol 2021;11:678847. [PMID: 34778023 DOI: 10.3389/fonc.2021.678847] [Reference Citation Analysis]
673 Wu X, Chapiro J, Malhotra A, Kothary N. Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. J Vasc Interv Radiol 2021;32:2-12.e1. [PMID: 33160827 DOI: 10.1016/j.jvir.2020.09.022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
674 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
675 Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shirakami Y, Suetsugu A, Shimizu M. Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers. Cancers (Basel) 2021;13:5980. [PMID: 34885089 DOI: 10.3390/cancers13235980] [Reference Citation Analysis]
676 Cao M, Zhang C, Zhou L. DNA methylation detection technology and plasma-based methylation biomarkers in screening of gastrointestinal carcinoma. Epigenomics 2021. [PMID: 34369810 DOI: 10.2217/epi-2021-0118] [Reference Citation Analysis]
677 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
678 Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol 2020;30:4150-63. [PMID: 32166493 DOI: 10.1007/s00330-020-06754-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
679 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
680 Pinto J, Azevedo R, Pereira E, Caldeira A. Ultrasonography in Gastroenterology: The Need for Training. GE Port J Gastroenterol 2018;25:308-16. [PMID: 30480048 DOI: 10.1159/000487156] [Reference Citation Analysis]
681 Horvat N, Monti S, Oliveira BC, Rocha CCT, Giancipoli RG, Mannelli L. State of the art in magnetic resonance imaging of hepatocellular carcinoma. Radiol Oncol. 2018;52:353-364. [PMID: 30511939 DOI: 10.2478/raon-2018-0044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
682 Yu R, Tan Z, Xiang X, Dan Y, Deng G. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer. 2017;17:608. [PMID: 28863782 DOI: 10.1186/s12885-017-3609-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
683 Li S, Huang P, Jeyarajan AJ, Ma C, Zhu K, Zhu C, Jiang N, Li M, Shao T, Han M, Tan L, Lin W. Assessment of Non-invasive Markers for the Prediction of Esophageal Variceal Hemorrhage. Front Med (Lausanne) 2021;8:770836. [PMID: 34926512 DOI: 10.3389/fmed.2021.770836] [Reference Citation Analysis]
684 Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology 2020;72:198-212. [PMID: 31698504 DOI: 10.1002/hep.31022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
685 Huang Y, Zhang Z, Zhou Y, Yang J, Hu K, Wang Z. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy? Onco Targets Ther. 2019;12:541-548. [PMID: 30666133 DOI: 10.2147/ott.s187357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
686 Kim H, An J, Park J, Park S, Lim Y, Lee E. Magnetic Resonance Imaging Is Cost‐Effective for Hepatocellular Carcinoma Surveillance in High‐Risk Patients With Cirrhosis. Hepatology 2019;69:1599-613. [DOI: 10.1002/hep.30330] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
687 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
688 Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison. J Magn Reson Imaging 2019;49:574-87. [PMID: 30102433 DOI: 10.1002/jmri.26199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
689 Li YC, Chen PH, Yeh JH, Hsiao P, Lo GH, Tan T, Cheng PN, Lin HY, Chen YS, Hsieh KC, Hsieh PM, Lin CW. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:418. [PMID: 34749663 DOI: 10.1186/s12876-021-01995-z] [Reference Citation Analysis]
690 Yue WW, Qi L, Wang DD, Yu SJ, Wang XJ, Xu HX, Wang SR. US-guided Microwave Ablation of Low-Risk Papillary Thyroid Microcarcinoma: Longer-Term Results of a Prospective Study. J Clin Endocrinol Metab. 2020;105:dgaa128. [PMID: 32198508 DOI: 10.1210/clinem/dgaa128] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
691 Carbonell G, Taouli B. Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. Magn Reson Imaging Clin N Am 2021;29:321-7. [PMID: 34243920 DOI: 10.1016/j.mric.2021.05.003] [Reference Citation Analysis]
692 Zhou Y, Liu F, Li C, Shi G, Xu X, Luo X, Zhang Y, Fu J, Zeng A, Chen L. Construction and Characterization of Adenovirus Vectors Encoding Aspartate-β-Hydroxylase to Preliminary Application in Immunotherapy of Hepatocellular Carcinoma. J Immunol Res 2018;2018:9832467. [PMID: 30116759 DOI: 10.1155/2018/9832467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
693 Cassinotto C, Nogue E, Morell M, Panaro F, Molinari N, Guiu B. Changing trends in hepatocellular carcinoma management: Results from a nationwide database in the last decade. Eur J Cancer 2021;146:48-55. [PMID: 33582392 DOI: 10.1016/j.ejca.2021.01.009] [Reference Citation Analysis]
694 Lim K, Kwon H, Cho J. Inter-reader agreement and imaging-pathology correlation of the LI-RADS M on gadoxetic acid-enhanced magnetic resonance imaging: efforts to improve diagnostic performance. Abdom Radiol (NY) 2020;45:2430-9. [PMID: 32008112 DOI: 10.1007/s00261-020-02421-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
695 Kim HI, Jang JK, Lim J, Chang S, An J, Kang HJ, Song GW, Lee SG, Kim SY, Shim JH. Hepatocyte-Specific Magnetic Resonance Imaging-Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis. Liver Transpl 2020;26:359-69. [PMID: 31756026 DOI: 10.1002/lt.25684] [Reference Citation Analysis]
696 Khan AA, Hadi YB, Thompson JM, Kupec JT. Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. BMJ Open Gastroenterol 2020;7:e000394. [PMID: 32398242 DOI: 10.1136/bmjgast-2020-000394] [Reference Citation Analysis]
697 Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. Nutrients 2020;12:E1076. [PMID: 32295043 DOI: 10.3390/nu12041076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
698 Tanaka M, Komatsu S, Kido M, Toyama H, Tominaga M, Uchida Y, Terashima K, Demizu Y, Okimoto T, Fukumoto T. Salvage hepatectomy for local recurrence after particle therapy using proton and carbon ion beams for liver cancer. Ann Gastroenterol Surg 2021;5:711-9. [PMID: 34585055 DOI: 10.1002/ags3.12468] [Reference Citation Analysis]
699 Qu C, Jiao Y, Wang Y. A liquid biopsy assay for identifying early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals. Mol Cell Oncol 2019;6:e1614419. [PMID: 31528693 DOI: 10.1080/23723556.2019.1614419] [Reference Citation Analysis]
700 Bryan N, Zandieh A, Kallakury B, Kaufman S, Yazigi N, Girlanda R, Hawksworth J, Fishbein T, Matsumoto C, Kroemer A, Khan K. De novo hepatocellular carcinoma 18 years after liver and small bowel transplantation in a one-year-old pediatric patient. Pediatr Transplant 2021;25:e13820. [PMID: 32844551 DOI: 10.1111/petr.13820] [Reference Citation Analysis]
701 Lopez-Lopez V, Robles-Campos R, Brusadin R, Lopez-Conesa A, de la Peña J, Caballero A, Arevalo-Perez J, Navarro-Barrios A, Gómez P, Parrilla-Paricio P. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization. Ann Transl Med 2019;7:691. [PMID: 31930092 DOI: 10.21037/atm.2019.10.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
702 Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. Onco Targets Ther 2018;11:7315-21. [PMID: 30498358 DOI: 10.2147/OTT.S175715] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
703 Hsieh MH, Kao TY, Hsieh TH, Kao CC, Peng CY, Lai HC, Chuang PH, Kao JT. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. PLoS One 2020;15:e0244293. [PMID: 33382703 DOI: 10.1371/journal.pone.0244293] [Reference Citation Analysis]
704 Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;12. [PMID: 31877664 DOI: 10.3390/cancers12010036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
705 Lee HS, Kim MJ, An C. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 2019;29:2408-16. [PMID: 30552477 DOI: 10.1007/s00330-018-5893-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
706 Liu D, Liu F, Xie X, Su L, Liu M, Kuang M, Huang G, Wang Y, Zhou H, Wang K, Lin M, Tian J. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol. 2020;30:2365-2376. [PMID: 31900703 DOI: 10.1007/s00330-019-06553-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 13.5] [Reference Citation Analysis]
707 Yuan G, Cheng X, Li Q, Zang M, Huang W, Fan W, Wu T, Ruan J, Dai W, Yu W, Chen M, Guo Y, Hu X, Chen J. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Onco Targets Ther 2020;13:12683-93. [PMID: 33328740 DOI: 10.2147/OTT.S286169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
708 Allaire M, Nault JC. Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:53-5. [PMID: 30881965 DOI: 10.21037/hbsn.2018.10.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
709 Innes H, McDonald SA, Hamill V, Yeung A, Dillon JF, Hayes PC, Went A, Fraser A, Bathgate A, Barclay ST, Janjua N, Goldberg DJ, Hutchinson SJ. Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: a population-based cohort study. Liver Int 2021. [PMID: 34951109 DOI: 10.1111/liv.15143] [Reference Citation Analysis]
710 Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 2021;157:140-52. [PMID: 34508996 DOI: 10.1016/j.ejca.2021.08.020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
711 Wang ZX, Li J, Wang EX, Xia DD, Bai W, Wang QH, Yuan J, Li XM, Niu J, Yin ZX, Xia JL, Fan DM, Han GH. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. World J Gastroenterol 2020; 26(15): 1805-1819 [PMID: 32351295 DOI: 10.3748/wjg.v26.i15.1805] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
712 Negussie AH, de Ruiter QMB, Britton H, Donahue DR, Boffi Q, Kim YS, Pritchard WF, Moonen C, Storm G, Lewis AL, Wood BJ. Synthesis, characterization, and imaging of radiopaque bismuth beads for image-guided transarterial embolization. Sci Rep 2021;11:533. [PMID: 33436734 DOI: 10.1038/s41598-020-79900-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
713 Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4:16. [PMID: 30115921 DOI: 10.1038/s41572-018-0014-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 195] [Article Influence: 47.8] [Reference Citation Analysis]
714 Bowlus CL, Lim JK, Lindor KD. AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.Clin Gastroenterol Hepatol. 2019;17:2416-2422. [PMID: 31306801 DOI: 10.1016/j.cgh.2019.07.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
715 Lyshchik A, Kono Y, Dietrich CF, Jang HJ, Kim TK, Piscaglia F, Vezeridis A, Willmann JK, Wilson SR. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY). 2018;43:861-879. [PMID: 29151131 DOI: 10.1007/s00261-017-1392-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
716 Tateishi R, Fujiwara N. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 195-224. [DOI: 10.1007/978-3-030-21540-8_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
717 Aliyari Ghasabeh M, Shaghaghi M, Pandey A, Ameli S, Ambale Venkatesh B, Jacob A, Pandey P, Hazhirkarzar B, Luo Y, Rezvani Habibabadi R, Khoshpouri P, Ghadimi M, Kamel IR. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). Eur Radiol 2021;31:1630-41. [PMID: 32910233 DOI: 10.1007/s00330-020-07251-4] [Reference Citation Analysis]
718 Gawrieh S, Dakhoul L, Miller E, Scanga A, deLemos A, Kettler C, Burney H, Liu H, Abu-Sbeih H, Chalasani N, Wattacheril J. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Aliment Pharmacol Ther 2019;50:809-21. [PMID: 31475372 DOI: 10.1111/apt.15464] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
719 Bucalau AM, Tancredi I, Pezzullo M, Leveque R, Picchia S, Laethem JV, Verset G. Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes. Hepat Oncol 2020;8:HEP31. [PMID: 33680430 DOI: 10.2217/hep-2020-0022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
720 Marschner CA, Zhang L, Schwarze V, Völckers W, Froelich MF, von Münchhausen N, Schnitzer ML, Geyer T, Fabritius MP, Rübenthaler J, Clevert DA. The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients1. Clin Hemorheol Microcirc 2020;76:453-8. [PMID: 33216017 DOI: 10.3233/CH-209221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
721 Kim Y, Lee HA, Lee JS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Seo YS, Kim SU. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma. Cancer Invest 2021;39:274-83. [PMID: 33356630 DOI: 10.1080/07357907.2020.1870126] [Reference Citation Analysis]
722 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2021. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Reference Citation Analysis]
723 Nevarez NM, Yopp AC. Challenging the Treatment Paradigm: Selecting Patients for Surgical Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Hepatocell Carcinoma 2021;8:851-60. [PMID: 34350140 DOI: 10.2147/JHC.S291530] [Reference Citation Analysis]
724 Jepsen P, Kraglund F, West J, Villadsen GE, Sørensen HT, Vilstrup H. Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis. J Hepatol 2020;73:1030-6. [PMID: 32512015 DOI: 10.1016/j.jhep.2020.05.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
725 Brunsing RL, Chen DH, Schlein A, Wolfson T, Gamst A, Mamidipalli A, Violi NV, Marks RM, Taouli B, Loomba R, Kono Y, Sirlin CB. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiol Imaging Cancer 2019;1:e190010. [PMID: 33778680 DOI: 10.1148/rycan.2019190010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
726 Sundarraj K, Raghunath A, Panneerselvam L, Perumal E. Fisetin Inhibits Autophagy in HepG2 Cells via PI3K/Akt/mTOR and AMPK Pathway. Nutrition and Cancer. [DOI: 10.1080/01635581.2020.1836241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
727 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1057] [Article Influence: 375.3] [Reference Citation Analysis]
728 Chen CC, Tung SY, Wei KL, Shen CH, Chang TS, Chen WM, Xu HW, Yen CW, Chen YH, Lu SN, Hung CH. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc 2020;119:532-7. [PMID: 31445848 DOI: 10.1016/j.jfma.2019.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
729 Yokota Y, Noda T, Okumura Y, Kobayashi S, Iwagami Y, Yamada D, Tomimaru Y, Akita H, Gotoh K, Takeda Y, Tanemura M, Murakami T, Umeshita K, Doki Y, Eguchi H. Serum exosomal miR-638 is a prognostic marker of HCC via downregulation of VE-cadherin and ZO-1 of endothelial cells. Cancer Sci 2021;112:1275-88. [PMID: 33426736 DOI: 10.1111/cas.14807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
730 Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Mitchell Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Lo Re V 3rd. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiol Biomarkers Prev 2020;29:71-8. [PMID: 31575557 DOI: 10.1158/1055-9965.EPI-19-0503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
731 Puigvehí M, Hashim D, Haber PK, Dinani A, Schiano TD, Asgharpour A, Kushner T, Kakked G, Tabrizian P, Schwartz M, Gurakar A, Dieterich D, Boffetta P, Friedman SL, Llovet JM, Saberi B. Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades. Am J Transplant 2020;20:220-30. [PMID: 31437349 DOI: 10.1111/ajt.15576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
732 Johnson AM, Dudek JM, Edwards DK, Myers TA, Joseph P, Laffin JJ, Bruinsma JJ. Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma. Expert Rev Mol Diagn 2021;:1-8. [PMID: 34581651 DOI: 10.1080/14737159.2021.1981290] [Reference Citation Analysis]
733 Zhao J, Wozniak A, Adams A, Cox J, Vittal A, Voss J, Bridges B, Weinman SA, Li Z. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway. J Exp Clin Cancer Res 2019;38:252. [PMID: 31196136 DOI: 10.1186/s13046-019-1246-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
734 Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? Med Sci Monit 2019;25:4941-51. [PMID: 31270311 DOI: 10.12659/MSM.916451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
735 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [